<SEC-DOCUMENT>0001437749-22-008983.txt : 20220414
<SEC-HEADER>0001437749-22-008983.hdr.sgml : 20220414
<ACCEPTANCE-DATETIME>20220414170100
ACCESSION NUMBER:		0001437749-22-008983
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220526
FILED AS OF DATE:		20220414
DATE AS OF CHANGE:		20220414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		22828054

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>mbrx20220406_def14a.htm
<DESCRIPTION>FORM DEF 14A
<TEXT>
<html><head>
	<title>mbrx20220406_def14a.htm</title>

	<!-- Generated by ThunderDome Portal - 4/14/2022 8:33:02 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>SCHEDULE 14A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">Proxy Statement Pursuant to Section 14(a) of</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Filed by the Registrant &#9746;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Filed by a Party other than the Registrant &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Check the appropriate box:</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">&#9744;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preliminary Proxy Statement</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Definitive Proxy Statement</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.3%;">&#9744;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Definitive Additional Materials</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Soliciting Material Pursuant to &#167;240.14a-12</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Moleculin Biotech,</b>&nbsp;<b>Inc.</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Registrant as Specified In Its Charter)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Payment of Filing Fee (Check the appropriate box):</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">No fee required.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fee paid previously with preliminary materials.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Moleculin Biotech,</b>&nbsp;<b>Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>5300 Memorial Drive, Suite 950</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Houston, TX 77007</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>(713)</b>&nbsp;<b>300-5160</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">To the Stockholders of Moleculin Biotech,&nbsp;Inc.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">You are cordially invited to attend the Annual Meeting of Stockholders of Moleculin Biotech,&nbsp;Inc. on May 26, 2022. The Annual Meeting will begin at 10:30 a.m. local time at the corporate offices of Moleculin Biotech, Inc., 5300 Memorial Drive, Suite 950, Houston, TX 77007.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Information regarding each of the matters to be voted on at the Annual Meeting is contained in the attached Proxy Statement and Notice of Annual Meeting of Stockholders. We urge you to read the proxy statement carefully. The proxy statement and proxy card are being mailed to all stockholders of record as of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Because it is important that your shares be voted at the Annual Meeting, we urge you to complete, date and sign the enclosed proxy card and return it as promptly as possible in the accompanying envelope, whether or not you plan to attend in person. Even after returning your proxy, if you are a stockholder of record and do attend the meeting and wish to vote your shares in person, you still may do so.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">We look forward to seeing you on May 26, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">We intend to hold our Annual Meeting in person and we look forward to seeing you on May 26, 2022. However, due to the uncertainties surrounding the impact of the coronavirus (COVID-19), it may not be possible or advisable to hold our Annual Meeting in person and we are planning for the possibility that the Annual Meeting may be held by means of remote communication. If we decide to take such step, we will announce the decision to do so in advance of the Annual Meeting. If we elect to hold our Annual Meeting by remote communication, details on how to participate will be issued by press release, posted on our website at http://ir.moleculin.com and filed with the U.S. Securities and Exchange Commission as additional proxy material.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Very truly yours,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">MOLECULIN BIOTECH,&nbsp;INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:2.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:21.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Walter V. Klemp</p>
			</td>
			<td style="vertical-align:bottom;width:26.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp</p>
			</td>
			<td style="vertical-align:bottom;width:26.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board and Chief Executive Officer</p>
			</td>
			<td style="vertical-align:bottom;width:26.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Important Notice Regarding the Availability of Proxy Materials</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>for the Annual Shareholder Meeting to be Held on May 26, 2022:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">Electronic Copies of the Proxy Statement and our 2021&nbsp;Annual Report on Form&nbsp;10-K are available at</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">https://materials.proxyvote.com/60855D</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Moleculin Biotech, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>5300 Memorial Drive, Suite 950</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Houston, TX 77007</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>(713)</b>&nbsp;<b>300-5160</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>To Be Held May 26, 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">TO THE STOCKHOLDERS OF MOLECULIN BIOTECH, INC.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">NOTICE IS HEREBY GIVEN that the 2022&nbsp;Annual Meeting of Stockholders of Moleculin Biotech, Inc. (the &#8220;Company&#8221;) will be held at the corporate offices at 5300 Memorial Drive, Suite 950, Houston, TX 77007, on May 26, 2022&nbsp;at 10:30 a.m., local time, for the following purposes, as described in the accompanying Proxy Statement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2023 annual meeting of stockholders of the Company or until such person&#8217;s successor is qualified and elected.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To ratify the appointment of Grant Thornton, LLP as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To approve an increase in the number of shares of common stock authorized for issuance under the Company's 2015 Stock Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To vote on a non-binding, advisory resolution to approve executive compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To vote on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To approve an amendment to the Company's amended and restated certificate of incorporation to eliminate supermajority voting requirements to amend the amended and restated certificate of incorporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To transact any other business that is properly brought before the Annual Meeting or any adjournment or postponement thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Only stockholders of record of the Company at the close of business on March 28, 2022&nbsp;are entitled to notice of and to vote at the Annual Meeting or any adjournment or postponement thereof. A complete list of these stockholders will be open for the examination of any stockholder of record at the Company&#8217;s principal executive offices located at 5300 Memorial Drive, Suite 950, Houston, TX 77007 for a period of ten days prior to the Annual Meeting. The list will also be available for the examination of any stockholder of record present at the Annual Meeting. The Annual Meeting may be adjourned or postponed from time to time without notice other than by announcement at the meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Company intends to hold the Annual Meeting in person. However, due to the uncertainties surrounding the impact of the coronavirus (COVID-19), it may not be possible or advisable to hold the Annual Meeting in person and the Company is planning for the possibility that the Annual Meeting may be held by means of remote communication. If the Company decides to take such step, it will announce the decision to do so in advance of the Annual Meeting. If the Company elects to hold the Annual Meeting by remote communication, details on how to participate will be issued by press release, posted on the Company&#8217;s website at http://ir.moleculin.com and filed with the U.S. Securities and Exchange Commission as additional proxy material.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, PLEASE SIGN AND DATE THE ENCLOSED PROXY AND RETURN IT IN THE ENVELOPE PROVIDED.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:18.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:32.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By Order of the Board of Directors,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:18.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:32.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:18.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:32.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MOLECULIN BIOTECH,&nbsp;INC.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:18.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:32.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Walter V. Klemp</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:18.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Houston, Texas</p>
			</td>
			<td style="vertical-align:bottom;width:32.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:18.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 14,&nbsp;2022</p>
			</td>
			<td style="vertical-align:bottom;width:32.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board and Chief Executive Officer</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;text-indent:6pt;"><b><a id="toc" name="toc" title="toc"></a>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:46.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4.4%; text-align: right;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#INFORMATION_ABOUT_THE_ANNUAL_MEETING_AND_VOTING" style="-sec-extract:exhibit;"><b><u>INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#INFORMATION_ABOUT_THE_ANNUAL_MEETING_AND_VOTING">1</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHY_DID_YOU_SEND_ME_THIS_PROXY_STATEMENT?" style="-sec-extract:exhibit;"><b><u>WHY DID YOU SEND ME THIS PROXY STATEMENT?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHY_DID_YOU_SEND_ME_THIS_PROXY_STATEMENT?">1</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHAT_PROPOSALS_WILL_BE_ADDRESSED_AT_THE_ANNUAL_MEETING?" style="-sec-extract:exhibit;"><b><u>WHAT PROPOSALS WILL BE ADDRESSED AT THE ANNUAL MEETING?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHAT_PROPOSALS_WILL_BE_ADDRESSED_AT_THE_ANNUAL_MEETING?">1</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHO_MAY_VOTE_ON_THESE_PROPOSALS?" style="-sec-extract:exhibit;"><b><u>WHO MAY VOTE ON THESE PROPOSALS?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHO_MAY_VOTE_ON_THESE_PROPOSALS?">1</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#HOW_MANY_VOTES_DO_I_HAVE?" style="-sec-extract:exhibit;"><b><u>HOW MANY VOTES DO I HAVE?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#HOW_MANY_VOTES_DO_I_HAVE?">1</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHY_WOULD_THE_ANNUAL_MEETING_BE_POSTPONED?" style="-sec-extract:exhibit;"><b><u>WHY WOULD THE ANNUAL MEETING BE POSTPONED?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHY_WOULD_THE_ANNUAL_MEETING_BE_POSTPONED?">1</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#HOW_DO_I_VOTE_BY_PROXY?" style="-sec-extract:exhibit;"><b><u>HOW DO I VOTE BY PROXY?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#HOW_DO_I_VOTE_BY_PROXY?">2</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#HOW_DO_I_VOTE_IN_PERSON?" style="-sec-extract:exhibit;"><b><u>HOW DO I VOTE IN PERSON?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#HOW_DO_I_VOTE_IN_PERSON?">2</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#MAY_I_REVOKE_MY_PROXY?" style="-sec-extract:exhibit;"><b><u>MAY I REVOKE MY PROXY?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#MAY_I_REVOKE_MY_PROXY?">2</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHAT_VOTE_IS_REQUIRED_TO_APPROVE_EACH_PROPOSAL?" style="-sec-extract:exhibit;"><b><u>WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHAT_VOTE_IS_REQUIRED_TO_APPROVE_EACH_PROPOSAL?">2</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ARE_THERE_ANY_RIGHTS_OF_APPRAISAL?" style="-sec-extract:exhibit;"><b><u>ARE THERE ANY RIGHTS OF APPRAISAL?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#ARE_THERE_ANY_RIGHTS_OF_APPRAISAL?">3</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHO_BEARS_THE_COST_OF_SOLICITING_PROXIES?" style="-sec-extract:exhibit;"><b><u>WHO BEARS THE COST OF SOLICITING PROXIES?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHO_BEARS_THE_COST_OF_SOLICITING_PROXIES?">3</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHERE_ARE_MOLECULIN&#8217;S_PRINCIPAL_EXECUTIVE_OFFICES?" style="-sec-extract:exhibit;"><b><u>WHERE ARE MOLECULIN</u></b>&#8217;<b><u>S PRINCIPAL EXECUTIVE OFFICES?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHERE_ARE_MOLECULIN&#8217;S_PRINCIPAL_EXECUTIVE_OFFICES?">3</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#HOW_CAN_I_OBTAIN_ADDITIONAL_INFORMATION_ABOUT_MOLECULIN?" style="-sec-extract:exhibit;"><b><u>HOW CAN I OBTAIN ADDITIONAL INFORMATION ABOUT MOLECULIN?</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#HOW_CAN_I_OBTAIN_ADDITIONAL_INFORMATION_ABOUT_MOLECULIN?">3</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#STOCK_OWNERSHIP_OF_CERTAIN_BENEFICIAL_OWNERS_AND_MANAGEMENT" style="-sec-extract:exhibit;"><b><u>STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#STOCK_OWNERSHIP_OF_CERTAIN_BENEFICIAL_OWNERS_AND_MANAGEMENT">4</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#INFORMATION_ABOUT_DIRECTORS_AND_EXECUTIVE_OFFICERS" style="-sec-extract:exhibit;"><b><u>INFORMATION ABOUT DIRECTORS AND EXECUTIVE OFFICERS</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#INFORMATION_ABOUT_DIRECTORS_AND_EXECUTIVE_OFFICERS">5</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#GOVERNANCE_OF_THE_COMPANY" style="-sec-extract:exhibit;"><b><u>GOVERNANCE OF THE COMPANY</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#GOVERNANCE_OF_THE_COMPANY">7</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#COMPENSATION_OF_DIRECTORS_AND_EXECUTIVE_OFFICERS" style="-sec-extract:exhibit;"><b><u>COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#COMPENSATION_OF_DIRECTORS_AND_EXECUTIVE_OFFICERS">9</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#RELATED_PARTY_TRANSACTIONS" style="-sec-extract:exhibit;"><b><u>RELATED PARTY TRANSACTIONS</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#RELATED_PARTY_TRANSACTIONS">14</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROPOSAL_1:_ELECTION_OF_DIRECTORS" style="-sec-extract:exhibit;"><b><u>PROPOSAL 1: ELECTION OF DIRECTORS</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROPOSAL_1:_ELECTION_OF_DIRECTORS">15</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROPOSAL_2:_TO_RATIFY_THE_APPOINTMENT_OF_INDEPENDENT_REGISTERED_PUBLIC_" style="-sec-extract:exhibit;"><b><u>PROPOSAL 2: TO RATIFY THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROPOSAL_2:_TO_RATIFY_THE_APPOINTMENT_OF_INDEPENDENT_REGISTERED_PUBLIC_">15</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#AUDIT_COMMITTEE_REPORT" style="-sec-extract:exhibit;"><b><u>AUDIT COMMITTEE REPORT</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#AUDIT_COMMITTEE_REPORT">16</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROPOSAL_3:_TO_APPROVE_AN_INCREASE_IN_THE_NUMBER_OF_SHARES_OF_COMMON_STOCK_AUTHORIZED_FOR_ISSUANCE_UNDER_THE_2015_PLAN." style="-sec-extract:exhibit;"><b><u>PROPOSAL 3: TO APPROVE AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2015 PLAN</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROPOSAL_3:_TO_APPROVE_AN_INCREASE_IN_THE_NUMBER_OF_SHARES_OF_COMMON_STOCK_AUTHORIZED_FOR_ISSUANCE_UNDER_THE_2015_PLAN.">17</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROPOSAL_4:_TO_VOTE_ON_A_NON-BINDING,_ADVISORY_RESOLUTION_TO_APPROVE_EXECUTIVE_COMPENSATION" style="-sec-extract:exhibit;"><b><u>PROPOSAL 4: TO VOTE ON A NON-BINDING, ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROPOSAL_4:_TO_VOTE_ON_A_NON-BINDING,_ADVISORY_RESOLUTION_TO_APPROVE_EXECUTIVE_COMPENSATION">20</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROPOSAL_5:_TO_VOTE_ON_A_NON-BINDING,_ADVISORY_PROPOSAL_ON_THE_FREQUENCY_OF_HOLDING_FUTURE_VOTES_REGARDING_EXECUTIVE_COMPENSATION" style="-sec-extract:exhibit;"><b><u>PROPOSAL 5: TO VOTE ON A NON-BINDING, ADVISORY PROPOSAL ON THE FREQUENCY OF HOLDING FUTURE VOTES REGARDING EXECUTIVE COMPENSATION</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROPOSAL_5:_TO_VOTE_ON_A_NON-BINDING,_ADVISORY_PROPOSAL_ON_THE_FREQUENCY_OF_HOLDING_FUTURE_VOTES_REGARDING_EXECUTIVE_COMPENSATION">21</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROPOSAL_6:_TO_APPROVE_AN_AMENDMENT_TO_THE_COMPANY'S_AMENDED_AND_RESTATED_CERTIFICATE_OF_INCORPORATION_TO_ELIMINATE_SUPERMAJORITY_VOTING_REQUIREMENTS_TO_AMEND_THE_AMENDED_AND_RESTATED_CERTIFICATE_OF_INCORPORATION" style="-sec-extract:exhibit;"><b><u>PROPOSAL 6: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING REQUIREMENTS TO AMEND THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROPOSAL_6:_TO_APPROVE_AN_AMENDMENT_TO_THE_COMPANY'S_AMENDED_AND_RESTATED_CERTIFICATE_OF_INCORPORATION_TO_ELIMINATE_SUPERMAJORITY_VOTING_REQUIREMENTS_TO_AMEND_THE_AMENDED_AND_RESTATED_CERTIFICATE_OF_INCORPORATION">22</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#AVAILABILITY_OF_ANNUAL_REPORT_ON_FORM_10-K" style="-sec-extract:exhibit;"><b><u>AVAILABILITY OF ANNUAL REPORT ON FORM 10-K</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#AVAILABILITY_OF_ANNUAL_REPORT_ON_FORM_10-K">23</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#OTHER_PROPOSED_ACTION" style="-sec-extract:exhibit;"><b><u>OTHER PROPOSED ACTION</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#OTHER_PROPOSED_ACTION">23</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#HOUSEHOLDING_OF_PROXY_MATERIALS" style="-sec-extract:exhibit;"><b><u>HOUSEHOLDING OF PROXY MATERIALS</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#HOUSEHOLDING_OF_PROXY_MATERIALS">23</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:46.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#STOCKHOLDER_PROPOSALS_AND_SUBMISSIONS" style="-sec-extract:exhibit;"><b><u>STOCKHOLDER PROPOSALS AND SUBMISSIONS</u></b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#STOCKHOLDER_PROPOSALS_AND_SUBMISSIONS">23</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 46.4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><a href="#Annex_A" style="-sec-extract:exhibit;">ANNEX A</a></b></td>
			<td style="vertical-align: bottom; width: 4.4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><a class="tocPGNUM" href="#Annex_A">24</a></td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 46.4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><a href="#Annex_B" style="-sec-extract:exhibit;"><b>ANNEX B</b></a></td>
			<td style="vertical-align: bottom; width: 4.4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><a class="tocPGNUM" href="#Annex_B">25</a></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>MOLECULIN BIOTECH, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>PROXY STATEMENT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>FOR</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>ANNUAL MEETING OF STOCKHOLDERS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>To Be Held May 26, 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b><a id="INFORMATION_ABOUT_THE_ANNUAL_MEETING_AND_VOTING" name="INFORMATION ABOUT THE ANNUAL MEETING AND VOTING" title="INFORMATION ABOUT THE ANNUAL MEETING AND VOTING"></a>INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHY_DID_YOU_SEND_ME_THIS_PROXY_STATEMENT?" name="WHY DID YOU SEND ME THIS PROXY STATEMENT?" title="WHY DID YOU SEND ME THIS PROXY STATEMENT?"></a>WHY DID YOU SEND ME THIS PROXY STATEMENT?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">This proxy statement and the enclosed proxy card are furnished in connection with the solicitation of proxies by the Board of Directors of Moleculin Biotech, Inc., a Delaware corporation, for use at the Annual Meeting of Moleculin Biotech Inc.'s stockholders to be held at the 5300 Memorial Drive, Suite 950, Houston, TX 77007, on May 26, 2022&nbsp;at 10:30 a.m., local time, and at any adjournments or postponements of the Annual Meeting. This proxy statement summarizes the information you need to make an informed vote on the proposals to be considered at the Annual Meeting. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card using the envelope provided. The terms &#8220;Moleculin,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our&#8221; refer to Moleculin Biotech, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHAT_PROPOSALS_WILL_BE_ADDRESSED_AT_THE_ANNUAL_MEETING?" name="WHAT PROPOSALS WILL BE ADDRESSED AT THE ANNUAL MEETING?" title="WHAT PROPOSALS WILL BE ADDRESSED AT THE ANNUAL MEETING?"></a>WHAT PROPOSALS WILL BE ADDRESSED AT THE ANNUAL MEETING?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">We will address the following proposals at the Annual Meeting:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2023 annual meeting of stockholders of the Company or until such person&#8217;s successor is qualified and elected.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To ratify the appointment of Grant Thornton, LLP as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To approve an increase in the number of shares of common stock authorized for issuance under the Company's 2015 Stock&nbsp;Plan (the "2015 Plan").</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To vote on a non-binding, advisory resolution to approve executive compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To vote on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To approve an amendment to the Company's amended and restated certificate of incorporation to eliminate supermajority voting requirements to amend the amended and restated certificate of incorporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To transact any other business that is properly brought before the Annual Meeting or any adjournment or postponement thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHO_MAY_VOTE_ON_THESE_PROPOSALS?" name="WHO MAY VOTE ON THESE PROPOSALS?" title="WHO MAY VOTE ON THESE PROPOSALS?"></a>WHO MAY VOTE ON THESE PROPOSALS?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We will send this proxy statement, the attached Notice of Annual Meeting and the enclosed proxy card on or about April 14, 2022&nbsp;to all stockholders as of March 28, 2022&nbsp;(the &#8220;Record Date&#8221;). Stockholders who owned shares of our common stock at the close of business on the Record Date are entitled to vote at the Annual Meeting on all matters properly brought before the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">On the Record Date, we had 28,578,338&nbsp;shares of issued and outstanding common stock entitled to vote at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="HOW_MANY_VOTES_DO_I_HAVE?" name="HOW MANY VOTES DO I HAVE?" title="HOW MANY VOTES DO I HAVE?"></a>HOW MANY VOTES DO I HAVE?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Each share of common stock is entitled to one vote on each matter presented at the Annual Meeting. Cumulative voting is not permitted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHY_WOULD_THE_ANNUAL_MEETING_BE_POSTPONED?" name="WHY WOULD THE ANNUAL MEETING BE POSTPONED?" title="WHY WOULD THE ANNUAL MEETING BE POSTPONED?"></a>WHY WOULD THE ANNUAL MEETING BE POSTPONED?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Annual Meeting will be postponed if a quorum is not present on May 26, 2022. The presence in person or by proxy of at least a majority of our common stock outstanding as of the Record Date will constitute a quorum and is required to transact business at the Annual Meeting. If a quorum is not present, the Annual Meeting may be adjourned until a quorum is obtained.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Abstentions and broker non-votes are treated as shares present or represented at the meeting, but are not counted as votes cast. Shares held by brokers who do not have discretionary authority to vote on a particular matter and who have not received voting instructions from their customers (broker non-votes) are not considered to be "entitled to vote" on that matter and are not counted or deemed to be present or represented for the purpose of determining whether stockholders have approved that matter, but they are counted as present for the purposes of determining the existence of a quorum at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="HOW_DO_I_VOTE_BY_PROXY?" name="HOW DO I VOTE BY PROXY?" title="HOW DO I VOTE BY PROXY?"></a>HOW DO I VOTE BY PROXY?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Whether you plan to attend the Annual Meeting or not, we urge you to complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. Returning the proxy card will not affect your right to attend the Annual Meeting and vote in person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If you properly fill in your proxy card and send it to us in time to vote, your proxy (one of the individuals named on your proxy card) will vote your shares as you have directed. If you sign the proxy card but do not make specific choices, your proxy will vote your shares as recommended by the Board of Directors (the "Board") as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR the election of the Board&#8217;s six nominees to our Board of Directors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR ratification of the appointment of Grant Thornton, LLP as our independent registered public accounting firm for the year ending December 31, 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR approving an increase in the number of shares of common stock authorized for issuance under the 2015 Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR adopting a non-binding, advisory resolution to approve executive compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR approving a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR approving an amendment to the Company's amended and restated certificate of incorporation to eliminate supermajority voting requirements to amend the amended and restated certificate of incorporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In their discretion, upon such other matters as may property come before the meeting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">If any other matters are presented, your proxy will vote in accordance with his or her best judgment. At the time this proxy statement was printed, we knew of no matters that needed to be acted on at the Annual Meeting other than those discussed in this proxy statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="HOW_DO_I_VOTE_IN_PERSON?" name="HOW DO I VOTE IN PERSON?" title="HOW DO I VOTE IN PERSON?"></a>HOW DO I VOTE IN PERSON?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If you plan to attend the Annual Meeting and vote in person on May 26, 2022, or at a later date if the meeting is adjourned or postponed, we will give you a ballot when you arrive. However, if your shares are held in the name of your broker, bank or other nominee, you must bring a power of attorney executed by the broker, bank or other nominee that owns the shares of record for your benefit and authorizing you to vote the shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="MAY_I_REVOKE_MY_PROXY?" name="MAY I REVOKE MY PROXY?" title="MAY I REVOKE MY PROXY?"></a>MAY I REVOKE MY PROXY?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">If you give a proxy, you may revoke it at any time before it is exercised. You may revoke your proxy in three ways:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">You may send in another proxy with a later date.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">You may notify us in writing (or if the stockholder is a corporation, under its corporate seal, by an officer or attorney of the corporation) at our principal executive offices before the Annual Meeting that you are revoking your proxy.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">You may vote in person at the Annual Meeting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHAT_VOTE_IS_REQUIRED_TO_APPROVE_EACH_PROPOSAL?" name="WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL?" title="WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL?"></a>WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 52pt;"><b>Proposal 1: Election of Directors</b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">A plurality of the eligible votes cast is required to elect director nominees, and as such, the six&nbsp;nominees who receive the greatest number of &#8220;FOR&#8221; votes cast by stockholders, entitled to vote at the meeting, will be elected. A nominee who receives a plurality means he or she has received more &#8220;FOR&#8221; votes than any other nominee for the same director&#8217;s seat. Broker non-votes will have no effect on this proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b>Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 2 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal. We believe this proposal will be considered to be a &#8220;routine&#8221; matter and, accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority to vote on this proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b>Proposal 3: To approve an increase in the number of shares of common stock authorized for issuance under the 2015 Plan.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 3 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b>Proposal 4: To vote on a non-binding, advisory resolution to approve executive compensation.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 4 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b>Proposal 5: To vote on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 5 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b>Proposal 6: To approve an amendment to the Company's amended and restated certificate of incorporation to eliminate supermajority voting requirements to amend the amended and restated certificate of incorporation.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 6 requires the affirmative vote of two-thirds of our outstanding shares entitled to vote on the matter. Broker non-votes and abstentions will be counted as votes against the proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b>Other Business That Is Properly Brought Before the Annual Meeting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If you do not give instructions to your bank or brokerage firm, it will nevertheless be entitled to vote your shares in its discretion on routine matters. However, absent your instructions, the record holder will not be permitted to vote your shares on a non-routine matter, which are referred to as "broker non-votes", properly brought before the meeting. Broker non-votes (shares held by brokers that do not have discretionary authority to vote on the matter and have not received voting instructions from their clients) are not counted or deemed to be present or represented for the purpose of determining whether stockholders have approved that proposal, but will be counted in determining whether there is a quorum present.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="ARE_THERE_ANY_RIGHTS_OF_APPRAISAL?" name="ARE THERE ANY RIGHTS OF APPRAISAL?" title="ARE THERE ANY RIGHTS OF APPRAISAL?"></a>ARE THERE ANY RIGHTS OF APPRAISAL?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">The Board of Directors is not proposing any action for which the laws of the State of Delaware, our certificate of incorporation or our bylaws provide a right of a stockholder to obtain appraisal of or payment for such stockholder&#8217;s shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHO_BEARS_THE_COST_OF_SOLICITING_PROXIES?" name="WHO BEARS THE COST OF SOLICITING PROXIES?" title="WHO BEARS THE COST OF SOLICITING PROXIES?"></a>WHO BEARS THE COST OF SOLICITING PROXIES?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We will bear the cost of soliciting proxies in the accompanying form and will reimburse brokerage firms and others for expenses involved in forwarding proxy materials to beneficial owners or soliciting their execution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We have engaged Okapi Partners LLC (&#8220;Okapi&#8221;) to assist us in soliciting proxies for the Annual Meeting. We will pay Okapi a base fee of $10,000, plus reasonable out-of-pocket expenses. We estimate the total amount payable to Okapi will be approximately $15,000.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="WHERE_ARE_MOLECULIN&#8217;S_PRINCIPAL_EXECUTIVE_OFFICES?" name="WHERE ARE MOLECULIN&#8217;S PRINCIPAL EXECUTIVE OFFICES?" title="WHERE ARE MOLECULIN&#8217;S PRINCIPAL EXECUTIVE OFFICES?"></a>WHERE ARE MOLECULIN</b>&#8217;<b>S PRINCIPAL EXECUTIVE OFFICES?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The principal executive offices of Moleculin are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007 and our telephone number is (713)&nbsp;300-5160.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="HOW_CAN_I_OBTAIN_ADDITIONAL_INFORMATION_ABOUT_MOLECULIN?" name="HOW CAN I OBTAIN ADDITIONAL INFORMATION ABOUT MOLECULIN?" title="HOW CAN I OBTAIN ADDITIONAL INFORMATION ABOUT MOLECULIN?"></a>HOW CAN I OBTAIN ADDITIONAL INFORMATION ABOUT MOLECULIN?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, which requires that we file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding companies, including Moleculin, that file electronically with the SEC. The SEC&#8217;s website address is www.sec.gov. In addition, our filings may be inspected and copied at the public reference facilities of the SEC located at 100 F Street, N.E. Washington, DC 20549.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b><a id="STOCK_OWNERSHIP_OF_CERTAIN_BENEFICIAL_OWNERS_AND_MANAGEMENT" name="STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT" title="STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT"></a>STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">The following table sets forth information, as of March 28, 2022, regarding beneficial ownership of our common stock by:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;each of our directors;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;each of our named executive officers;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;all directors and executive officers as a group; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;each person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Beneficial ownership is determined according to the rules of the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole or shared voting or investment power of that security and includes options that are currently exercisable or exercisable within 60 days. Each director or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise indicated, we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us, have sole investment and voting power with respect to their shares, except where community property laws may apply. Except as otherwise noted below, the address for each person or entity listed in the table is c/o Moleculin Biotech, Inc., 5300 Memorial Drive, Suite 950, Houston, Texas 77007.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:30.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="7" style="border-bottom:solid 3px #000000;vertical-align:bottom;width:18.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>As of March 28, 2022</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:30.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares</b>&nbsp;<b>beneficially</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>owned</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percent of Class (1)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Name of Beneficial Owner</u></b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:8.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">614,000</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2.1</p>
			</td>
			<td style="vertical-align:bottom;width:0.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Donald Picker</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">214,982</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Less than 1%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">175,544</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Less than 1%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert George</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">24,335</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Less than 1%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Cannon</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">24,168</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(6)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Less than 1%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John Climaco</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21,668</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(6)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Less than 1%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Elizabeth Cermak&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9,723</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(6)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Less than 1%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joy Yan</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:7.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:30.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Directors and Named Executive Officers as a Group (8</i></b>&nbsp;<b><i>persons)</i></b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,084,420</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(7)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.7</p>
			</td>
			<td style="vertical-align:bottom;width:0.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(1) Based on 28,578,338&nbsp;shares of common stock outstanding as of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(2) Includes 238,500&nbsp;shares held by AnnaMed, Inc. that have been included in the amount for Mr. Klemp. Mr. Klemp has voting and dispositive power over the shares held by AnnaMed, Inc. Includes 183,099&nbsp;shares underlying options exercisable within 60 days of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(3) Of the amount in the table, 105,000&nbsp;shares held by IntertechBio Corp. have been included in the amounts for Dr. Picker. Dr. Picker shares&nbsp;voting and dispositive power over the shares held by IntertechBio Corp. Includes 31,876&nbsp;shares underlying options exercisable within 60 days of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(4) Includes 173,877&nbsp;shares underlying options exercisable within 60 days of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(5) Includes 24,168&nbsp;shares underlying options exercisable within 60 days of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(6) Consists solely of shares underlying options exercisable within 60 days of March 28, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(7) Consists of the shares identified in footnotes (2)-(6).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="INFORMATION_ABOUT_DIRECTORS_AND_EXECUTIVE_OFFICERS" name="INFORMATION ABOUT DIRECTORS AND EXECUTIVE OFFICERS" title="INFORMATION ABOUT DIRECTORS AND EXECUTIVE OFFICERS"></a>INFORMATION ABOUT DIRECTORS AND EXECUTIVE OFFICERS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Directors and Executive Officers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">The following table sets forth the names and ages of all of our directors and executive officers as of March 28, 2022. Our officers are appointed by, and serve at the pleasure of, the Board of Directors. &nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">62</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board, President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer and Executive Vice President</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Donald Picker</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">76</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Scientific Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Paul Waymack</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">69</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Senior Chief Medical Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert E. George</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">71</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael D. Cannon</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">76</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John Climaco</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">53</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Elizabeth A. Cermak&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">64</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:19.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joy Yan</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">42</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Set forth below is biographical information about each of the individuals named in the tables above:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Walter V. Klemp - Chairman of the Board, President and Chief Executive Officer</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Mr. Klemp is a co-founder of our company, and has served as our chairman of the board and chief executive officer since July 2015 and as president since August 2017.&nbsp;Since July 2018, Mr. Klemp has served as executive chairman on the board of directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. From November 2011 to July 2018, Mr. Klemp served as chief executive officer of Soliton. Mr. Klemp served as president and chief executive officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as chief executive officer and chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America&#8217;s Fastest Growing Companies. We believe that Mr. Klemp&#8217;s history with our company and background, coupled with his extensive experience in the medical field, provide him with the qualifications to serve as a Chairman of the Board and CEO.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Jonathan P. Foster - Chief Financial Officer and Executive Vice President</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Mr. Foster has served as our chief financial officer and executive vice president since August 2016. Mr. Foster brings more than 30 years in financial experience holding a variety of executive and senior financial positions with public, private, start-up to large corporate and international companies. From February 2012 to August 2016, Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Prior to that Mr. Foster served in various C-suite capacities with public and private companies with his start beginning as Manager at Deloitte &amp; Touche, LLP.&nbsp;Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and from June 2018 until December 2021 served on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he was the chair of the Audit and Compensation Committees and the past chair of the Nominating &amp; Governance Committee.&nbsp;In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. Since June 2021, Mr. Foster has served on the Board of Directors of Volcon, Inc. where he is the past chair and current member of the Audit Committee, a member of the Nominating &amp; Governance Committee and is the Chair of the Compensation Committee. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 16pt; text-indent: 36pt;"><b><i>Donald Picker, PhD - Chief Scientific Officer</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Dr. Picker has served as our chief scientific officer since August 2017 after serving as our chief operating officer from July 2015 until August 2017 and as our president from January 2016 to August 2017.&nbsp;From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006. Dr. Picker led the development of carboplatin and cisplatin from concept to FDA approval.&nbsp;From 2018 to 2019, Dr. Picker served on the board of directors of CNS Pharmaceuticals, Inc., and Dr. Picker currently serves as the Chief Science Officer of CNS Pharmaceuticals, Inc. on a part-time basis. Dr. Picker received his BS degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only part of his work time to us, and provides services as needed to us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Paul Waymack, Senior Chief Medical Officer</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Dr. Waymack&nbsp;was the Chairman of the Board of Directors and CMO of Kitov Pharmaceuticals, and its precursor, from 2010 to 2019 and brings over 30 years&#8217; experience in the biopharmaceutical field. A former academic transplant surgeon and FDA medical officer, Dr. Waymack has over 20 years&#8217; experience as a drug development consultant for major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10-year academic career, Dr. Waymack published over 100 scientific articles, mainly in the fields of prostaglandins and immunology. In addition, he was commissioned and served as a Major in the US Army Medical Corps in the position of Chief of Surgical Research at the Institute for Surgical Research. Dr. Waymack was also an Associate Professor of Surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey. Dr. Waymack is currently devoting only part of his work time to us and provides services as needed to us.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Robert E. George</i></b> - <b><i>Director</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Mr. George joined our board of directors upon our IPO. He was a partner with the international accounting firm of PricewaterhouseCoopers (PWC) for 27 years until 2010, where his client service sectors included healthcare, among others. Mr. George currently serves as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, since June 2011, has been a member of The University of Texas at Austin, McCombs Graduate School of Business accounting faculty. Mr. George has a B.B.A. - Accounting (cum laude) from the University of North Texas. We believe Mr. George&#8217;s deep and broad level of expertise in financial accounting and reporting matters, particularly in the healthcare sector, as a former audit partner at PricewaterhouseCoopers provide him with the qualifications to serve as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Michael D. Cannon - Director</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Mr. Cannon joined our board of directors upon our IPO. Between 1997 and 2004, Mr. Cannon was the Chief Science Officer, EVP and a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc. SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and generic biopharmaceuticals. While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December 2009, Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing in health care investments. From May 2005 until December 2011, Mr. Cannon was a partner in a private partnership formed to evaluate and perform preliminary development of intellectual property in the healthcare sector. Since 2005, Mr. Cannon has served as a board member for several private companies. Mr. Cannon currently serves on the boards of directors of three privately held biotech companies. He previously served on the board of directors of Athenex, Inc., a public company traded on the NASDAQ. Mr. Cannon has a degree in chemistry from Fordham College. We believe Mr. Cannon&#8217;s distinguished career in the biotechnology field, particularly as Chief Science Officer, EVP and a Director of SICOR, a publicly traded company, provide him with the qualifications to serve as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>John M. Climaco, Esq. - Director</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Mr. Climaco joined our board of directors in July 2017. Mr. Climaco has served as the chief executive officer of CNS Pharmaceuticals, Inc. since September 2017. Mr. Climaco has served in leadership roles in a variety of healthcare companies. From 2014 until 2017, Mr. Climaco served as the Executive Vice &#8208;President of Perma&#8208;Fix Medical S.A. From 2002 until 2012, Mr. Climaco served as President and CEO of Axial Biotech, Inc., a DNA diagnostics company. Mr. Climaco previously&nbsp;served&nbsp;as a director of Digirad, Inc., a leading national provider of imaging services;&nbsp;PDI, Inc., a provider of outsourced commercial services to pharma companies;&nbsp;InfuSystem Holdings, Inc., the largest supplier of infusion services to oncologists in the United States; and Birner Dental Management Services, Inc., a provider of practice management services to the dental industry. Mr. Climaco obtained his Juris Doctorate Degree from University of California Hastings College of Law, San Francisco, CA and a Bachelors of Philosophy from Middlebury College, Middlebury, VT. Mr. Climaco is active with the State Bar of Utah. We believe Mr. Climaco&#8217;s vast experience with development stage companies and his legal background provides him with the qualifications to serve as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Elizabeth Cermak - Director</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Ms. Cermak joined our board of directors in October 2020. Ms.&nbsp;Cermak has held numerous board positions in the healthcare space, including currently at Clarus Therapeutics, Inc., where she serves as an Independent Board Director. In addition, Ms. Cermak was formerly an Independent Board Director at Neurana Pharmaceuticals, QUE Oncology and&nbsp;SteadyMed Therapeutics. From 2009 to 2013,&nbsp;Ms. Cermak was the Chief Commercial Officer and Executive Vice President at POZEN, now Aralez Pharmaceuticals. As Chief Commercial Officer at POZEN, Ms. Cermak&nbsp;developed the commercial strategy and launch Plans for the Company's first self-marketed product, and signed licensing deals with Johnson &amp; Johnson, Desitin, and Sanofi. Prior to joining POZEN, Ms. Cermak&nbsp;worked at Johnson &amp; Johnson for 25 years, serving most recently as World-Wide Vice President Personal Products Franchise and Vice President Professional Sales &amp; Marketing, and leading the US Women's Health Pharmaceutical business. We believe Ms. Cermak&#8217;s extensive experience in the healthcare industry provides her with the qualifications to serve as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><b><i>Joy Yan</i></b>&nbsp;<b><i>-</i></b>&nbsp;<b><i>Director</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Dr. Yan is a biopharma executive and oncology physician-scientist with extensive experience in early and late clinical development with a successful track record leading the development of multiple oncology products from strategic planning through global submissions and approvals. Dr. Yan currently serves as an Independent Board Director at Checkmate Pharmaceuticals and Chief Medical Officer of Keymed Biosciences. She is also a member of the Scientific Advisory Board at Ambrx , after her role as the Chief Medical Officer, where she led the pipeline strategy and quickly advanced the development programs. She also assisted on the cross-over financing and IPO. Previously at Bristol Myers Squibb, she led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS&#8217; first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. She also has broad clinical development experience from her roles with Janssen and Bayer, where she led Phase 1, 2 and 3 studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, Bi-specifics, ADCs, TKIs) across multiple tumor types. Dr. Yan completed her Ph.D. in Biochemistry &amp; Molecular Biology at Johns Hopkins University. She received her M.D. from China Medical University and completed her residency and clinical fellowship at University of Washington. We believe Dr. Yan&#8217;s extensive experience with early and late clinical development&nbsp;provides her with the qualifications to serve as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">No director is related to any other director or executive officer of our company or our subsidiaries, and, there are no arrangements or understandings between a director and any other person pursuant to which such person was elected as director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="GOVERNANCE_OF_THE_COMPANY" name="GOVERNANCE OF THE COMPANY" title="GOVERNANCE OF THE COMPANY"></a>GOVERNANCE OF THE COMPANY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Our Board of Directors</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Board of Directors oversees the business affairs of Moleculin and monitors the performance of management. Pursuant to our Bylaws, the Board of Directors shall consist of no less than one director. Members of the Board of Directors discussed various business matters informally on numerous occasions throughout the year 2021. The Board held 23&nbsp;meetings during 2021. In addition to meetings of the full Board of Directors, our Board has established an Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee. In addition, during 2021 our Board established a&nbsp;Strategic Planning Committee, on an ad hoc basis for 2021, to assist in reviewing our drug development pipeline. During 2021, these Board committees held an additional 28&nbsp;meetings during the year. Specifically, the breakdown of the committee meetings for 2021&nbsp;are as follows: 9 for the Audit Committee, 9 for the Compensation Committee,&nbsp;7 for the Governance Committee, and 3 for the Strategic Planning Committee. We believe that such interaction between fellow Board members and with management provided proper oversight of the Company. Each incumbent director attended at least 90%&nbsp;of the total number of meetings of the Board of Directors and committee meetings of which such director was a member (held during the period for which such director was in office).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Director Independence</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The rules of the Nasdaq Stock Market, or the Nasdaq Rules, require a majority of a listed company&#8217;s board of directors to be composed of independent directors. In addition, the Nasdaq Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and governance committees be independent. Under the Nasdaq Rules, a director will only qualify as an independent director if, in the opinion of our Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Nasdaq Rules also require that audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In considering the independence of compensation committee members, the Nasdaq Rules require that our board of directors must consider additional factors relevant to the duties of a compensation committee member, including the source of any compensation we pay to the director and any affiliations with our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our board of directors undertook a review of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family relationships, our board of directors has determined that each of our directors, with the exception of Mr. Klemp, are independent as defined under the Nasdaq Rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Board Committees</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We established a Nominating and Corporate Governance Committee, an Audit Committee and a Compensation Committee. Our Board of Directors has adopted and approved a charter for each of these standing committees. The charters, which include the functions and responsibilities of each of the committees, can be found in the &#8220;Investors - Corporate Governance&#8221; section on our web site at www.moleculin.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Audit Committee</i>. The members of the Audit Committee are Robert George (Chairperson), Michael Cannon, John Climaco, and Elizabeth Cermak. Each member of the Audit Committee is independent as defined by the Nasdaq Rules. In addition, each member of the Audit Committee satisfies the additional requirements of the SEC and Nasdaq Rules for audit committee membership, including the additional independence requirements and the financial literacy requirements. The Board has determined that at least one member of the Audit Committee, Mr. George, is an &#8220;audit committee financial expert&#8221; as defined in the SEC&#8217;s rules and regulations. The primary purpose of the Audit Committee is to oversee the quality and integrity of our accounting and financial reporting processes and the audit of our financial statements. The Audit Committee is responsible for selecting, compensating, overseeing and terminating the selection of our independent registered public accounting firm.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Nominating and Corporate Governance Committee.</i> The members of the Nominating and Corporate Governance Committee are Robert George (Chairperson), Michael Cannon, John Climaco, and Elizabeth Cermak. Each member of the Nominating and Corporate Governance Committee is independent as defined by Nasdaq Rules. The primary functions and responsibilities of the Nominating and Corporate Governance Committee are to: (a) determine the qualifications, qualities, skills, and other expertise required to be a director; (b) identify and screen individuals qualified to become members of the Board; (c) make recommendations to the Board regarding the selection and approval of the nominees for director; and (d) review and assess the adequacy of our corporate governance policies and procedures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Compensation Committee</i>. The members of the Compensation Committee are Michael Cannon (Chairperson), Robert George,&nbsp;John Climaco, and Elizabeth Cermak. Each member of the Compensation Committee is independent as defined by Nasdaq Rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Compensation Committee is responsible for, among other things, reviewing and making recommendations to the Board of Directors with respect to the annual compensation for our Chief Executive Officer. The Compensation Committee also is responsible for reviewing and making recommendations to the Board of Directors the annual compensation and benefits for our other executive officers. The Compensation Committee also, among other things, reviews compensation of the Board, reviews and makes recommendations on all new executive compensation programs that are proposed for adoption and administers the Company&#8217;s equity incentive plans. The Compensation Committee is responsible for, among other things, reviewing and making recommendations to the Board of Directors with respect to the annual compensation for our Chief Executive Officer and Chief Financial Officer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Chief Executive Officer and Chief Financial Officer&nbsp;review&nbsp;the performance of our other executive officers (other than himself) and, based on that review, they then&nbsp;make recommendations to the Compensation Committee about the compensation of executive officers (other than themselves). Neither our Chief Executive Officer or Chief Financial Officer&nbsp;participate in any deliberations or approvals by the Board or the Compensation Committee with respect to their own compensation.&nbsp;In April 2018, the Compensation Committee retained Pay Governance, a compensation consulting firm, to evaluate our executive compensation program. Pay Governance&#8217;s engagement included assisting the Compensation Committee with the selection of a peer group of companies for benchmarking purposes, and an analysis of our existing executive compensation. The consultant serves at the pleasure of the Compensation Committee rather than management, and the consultant&#8217;s fees are approved by the Compensation Committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Board Member Attendance at Annual Meetings</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We do not have a formal policy regarding Board attendance at our annual meetings, however, all of our directors are invited to the annual meeting. Due to restrictions related to the COVID-19 pandemic, Mr. George was the only director who was able to attend the 2021 Annual Meeting of Stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Board Leadership Structure and Role in Risk Oversight</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Walter V. Klemp serves as both our Chief Executive Officer and Chairman of the Board. Our Board of Directors has no policy with regard to the separation of the offices of Chairman of the Board and Chief Executive Officer, and believes, given the size of our company, it is appropriate for Mr. Klemp to serve in both roles.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">John Climaco serves as the Lead Independent Director of our Board. As Lead Independent Director, Mr. Climaco is responsible for, among other things,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">leading executive sessions of the Board&#8217;s independent directors;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">serving as the principal liaison between the Chairman and the independent directors; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">approving all information sent to the Board of Directors and approving the agendas for all Board meetings.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Board believes that by maintaining a Lead Independent Director position, it has designed a governance structure that best advances Moleculin&#8217;s objectives, while maintaining proper checks and balances on senior management, and providing the independent members of the Board with open and transparent communication regarding our strategic planning activities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our management is responsible for managing risks in our business, including developing processes to manage and monitor risks. The Board views its role as one of oversight. The Board focuses on understanding management&#8217;s risk management systems, the effectiveness of those systems, and the way in which management proactively manages risks. In addition, the Board utilizes the Nominating and Corporate Governance Committee, the Audit Committee and the Compensation Committee to manage risks that arise under each committee&#8217;s area of focus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Nomination of Director Candidates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We receive suggestions for potential director nominees from many sources, including members of the Board, advisors, and stockholders. Any such nominations, together with appropriate biographical information, should be submitted to the Chairperson of the Nominating and Corporate Governance Committee in the manner discussed below. Any candidates submitted by a stockholder or stockholder group are reviewed and considered in the same manner as all other candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Qualifications for consideration as a Board nominee may vary according to the particular areas of expertise being sought as a complement to the existing board composition. However, minimum qualifications include high level leadership experience in business activities, breadth of knowledge about issues affecting the Company, experience on other boards of directors, preferably public company boards, and time available for meetings and consultation on Company matters. Our Nominating and Corporate Governance Committee does not have a formal policy with regard to the consideration of diversity in identifying director candidates, but seeks a diverse group of candidates who possess the background, skills and expertise to make a significant contribution to the Board, to the Company and our stockholders. Candidates whose evaluations are favorable are recommended by our Nominating and Corporate Governance Committee to the full Board for consideration. The full Board selects and recommends candidates for nomination as directors for stockholders to consider and vote upon at the annual meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">A stockholder wishing to nominate a candidate for election to our Board of Directors at any annual meeting at which the Board of Directors has determined that one or more directors will be elected must submit a written notice of his or her nomination of a candidate to the Chairperson of the Nominating and Corporate Governance Committee (c/o&nbsp;the Corporate Secretary), providing the candidates name, biographical data and other relevant information together with a consent from the nominee. Pursuant to our Bylaws, the submission must be received at our principal executive offices 120 days prior to the anniversary date of the mailing date of our previous year&#8217;s proxy statement so as to permit the Board of Directors time to evaluate the qualifications of the nominee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">During 2020, our Nominating and Corporate Governance Committee retained a third-party search firm to conduct a search to recruit a director. Ms. Cermak was recommended to our Nominating and Corporate Governance Committee by the third-party search firm. During 2021, our Nominating and Corporate Governance Committee retained a third-party search firm to conduct a search to recruit a director. Dr. Yan was recommended to our Nominating and Corporate Governance Committee by the third-party search firm. Except as set forth above, we have not employed an executive search firm, or paid a fee to any other third party, to locate qualified candidates for director positions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 31pt;"><b>Diversity of Directors </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 31pt;">The following table summarizes certain self-identified characteristics of our directors, utilizing the categories and terms set forth in applicable Nasdaq rules and related guidance (as of March 28, 2022):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Board Diversity Matrix (As of March 28, 2022)</b></p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Number of Directors</b></p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:15.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Female</b></p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Male</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Part I: Gender Identity</b></p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2</p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Directors</p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Part II: Demographic Information</b></p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Asian</p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1</p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:15.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">White</p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1</p>
			</td>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Stockholder Communications with Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Persons wishing to write to our Board of Directors, or to a specified director or committee of the Board, should send correspondence to the Corporate Secretary at 5300 Memorial Drive, Suite 950, Houston, Texas 77007. Electronic submissions of stockholder correspondence will not be accepted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Corporate Secretary will forward to the directors all communications that, in his or her judgment, are appropriate for consideration by the directors. Examples of communications that would not be appropriate for consideration by the directors include commercial solicitations and matters not relevant to the stockholders, to the functioning of the Board or to the affairs of Moleculin. Any correspondence received that is addressed generically to the Board of Directors will be forwarded to the Chairman of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Anti-Hedging Policy</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our policies prohibit directors, officers and other employees from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds), or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our equity securities without our prior approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Code of Ethics</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We have adopted a written code of ethics that applies to our directors, principal executive officer, principal financial officer, principal accounting officer or controller and any persons performing similar functions. The code of ethics is on the &#8220;Investors - Corporate Governance - Governance Documents&#8221; section of our web site at www.moleculin.com. We intend to disclose any future amendments to, or waivers from, the code of ethics within four business days of the waiver or amendment through a website posting or by filing a Current Report on Form 8-K with the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="COMPENSATION_OF_DIRECTORS_AND_EXECUTIVE_OFFICERS" name="COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS" title="COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS"></a>COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Executive Officer Compensation</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our named executive officers for the years ended December 31, 2021&nbsp;and 2020,&nbsp;which consist of our principal executive officer and our two other most highly compensated executive officers, are: (i) Walter V. Klemp, our chairman, president and chief executive officer; (ii) Jonathan P. Foster, our chief financial officer and executive vice president; and (ii) Donald Picker, our chief scientific officer.&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:11.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name and Principal Position</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Salary ($)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Non-Equity Incentive Plan Compensation ($)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock Awards ($) (5)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Option</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">awards</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">($) (1)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">All other</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">compensation</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">($) (2)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total ($)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:11.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp, Chairman, President - Chief Executive Officer (3)</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">537,917</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">317,725</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">373,000</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">722,657</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36,014</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,987,313</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:11.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">500,000</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">242,500</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">327,783</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">410,852</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">35,644</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,516,779</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:11.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster, Executive Vice President and Chief Financial Officer (4)</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">392,500</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">170,050</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">186,500</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">351,481</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">48,646</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,149,177</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:11.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">375,000</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">145,500</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">377,982</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">48,112</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">946,594</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:11.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Donald Picker, Chief Scientific Officer</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">323,333</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">136,040</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">202,532</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,492</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">682,397</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:11.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">300,000</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">117,875</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">82,171</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,281</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">520,327</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(1)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Represents the full grant date fair value of the option grant calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the named executive officer. For a summary of the assumptions made in the valuation of the awards, please see Note 6 to our financial statements as of and for the period ended December 31, 2021&nbsp;included in the Form 10-K provided to you along with this proxy statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents payments made by us for medical coverage, term life, dental vision, short and long-term disability, voluntary AD&amp;D and Voluntary life.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(3)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Mr. Klemp's equity awards in 2021 consisted of 223,635 stock options with a grant date fair value of $722,657, and 100,000 restricted stock units with a grant date fair value of $373,000. Mr. Klemp's equity awards in 2020 consisted of 83,334 stock options with a grant date fair value of $410,852, and 58,869 restricted stock units with a grant date fair value of $327,783.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(4)&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Mr. Foster's equity awards in 2021 consisted of 108,770 stock options with a grant date fair value of $351,481, and 50,000 restricted stock units with a grant date fair value of $186,500. Mr. Foster's equity awards in 2020 consisted of 76,667 stock options with a grant date fair value of $377,982, and no restricted stock units.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents the full grant date fair value of the restricted stock unit calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the named executive officer. For a summary of the assumptions made in the valuation of the awards, please see Note 6 to our financial statements as of and for the period ended December 31, 2021&nbsp;included in the Form 10-K provided to you along with this proxy statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Narrative to Summary Compensation Table</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We have established for compensation purposes a compensation year from June 1 until May 31 of each year. In June of each year, our compensation committee completes its annual review of executive compensation and determines, after researching comparable companies and using a leading industry survey, the compensation arrangements for the next compensation year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the individual executive&#8217;s performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. Our Compensation Committee typically reviews and discusses management&#8217;s proposed compensation with the Chief Executive Officer and Chief Financial Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, the Compensation Committee then determines the compensation for each executive officer. Our Compensation Committee, without members of management present, discusses and ultimately approves the compensation of our executive officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i><u>Compensation Consultant</u></i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In April 2018, the Compensation Committee retained Pay Governance, a compensation consulting firm, to evaluate our executive compensation program. Pay Governance&#8217;s engagement included assisting the Compensation Committee with the selection of a peer group of companies for benchmarking purposes, and an analysis of our existing executive compensation. The consultant serves at the pleasure of the Compensation Committee rather than us, and the consultant&#8217;s fees are approved by the Compensation Committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Annual Base Salary</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">For the 2020/2021&nbsp;compensation year, the base salaries for Mr. Klemp, Mr. Foster, and Dr. Picker were $500,000, $375,000, and $300,000, respectively.&nbsp;For the 2021/2022&nbsp;compensation year, the base salaries for Mr. Klemp, Mr. Foster, and Dr. Picker are $565,000, $405,000, and $340,000, respectively.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Annual Bonus and Non-Equity Incentive Plan Compensation.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We seek to motivate and reward our executives for achievements relative to our corporate goals and objectives, and with respect to their respective individual goals, for each fiscal year. For the 2020/2021&nbsp;compensation year, the target bonus for Mr. Klemp, Mr. Foster and Dr. Picker were 71%, 51%, and 51%, respectively, of their base salary. For the 2021/2022&nbsp;compensation year, the target bonus for Mr. Klemp, Mr. Foster and Dr. Picker are&nbsp;66%, 49%, and 47%,&nbsp;respectively, of their base salary. With respect to payment of bonuses, our Compensation Committee establishes certain &#8220;stretch goals&#8221; for our officers that permit a total potential bonus payable of 120% of the established target bonus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The actual performance-based annual bonus paid is calculated by multiplying the executive&#8217;s annual base salary, target bonus percentage, the percentage attainment of the corporate goals established by the Board for such year, which represents the total potential bonus payable to our named executive officers, and the percentage attainment of the individual goals approved by our Compensation Committee with respect to our other executive officers. However, the Compensation Committee is not required to calculate bonuses in this manner and retains discretion in the amounts it awards and the factors it takes into consideration in determining bonus amounts. At the end of the year, the Compensation Committee reviews our performance against our goals and objectives and approves the extent to which we achieved each of our corporate and individual goals and objectives, and, for each named executive officer, the amount of the bonus awarded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">For the 2020/2021&nbsp;compensation year, bonuses were awarded based on our achievement of specified corporate goals, including the progress of our clinical trials, the improvement of our internal controls and our ability to maintain sufficient funding, and individual goals, as applicable. Based on the level of achievement, our Compensation Committee awarded Mr. Klemp, Mr. Foster and Dr. Picker 90%, 89%, and 89%, respectively,&nbsp;of their potential bonuses for the 2020/2021&nbsp;compensation year. These actual bonus amounts are reflected in the "Non-Equity Incentive Plan Compensation" column of the Summary Compensation Table above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">For the 2021/2022&nbsp;compensation year, bonuses will be awarded based on our achievement of specified corporate goals, including the progress of our clinical trials, our business development efforts, the improvement in our cyber security efforts, and our ability to improve our balance sheet strength.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Long-Term Incentives</i></b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our 2015 Stock Plan provides for the grant of stock options, stock awards, stock unit awards and stock appreciation rights to key employees, non-employee directors and consultants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Each year our Compensation Committee establishes a value for the expected equity grant issuable to each of our named executive officers. For the 2020/2021&nbsp;compensation year, the fair value of the equity grants for Mr. Klemp, Mr. Foster and Dr. Picker were $955,000, $430,000 and $150,000, respectively. For the 2021/2022&nbsp;compensation year, the fair value of the equity grants for Mr. Klemp, Mr. Foster and Dr. Picker were established at $975,000, $430,000 and $175,000, respectively, although the final determination for any equity grants remain at the discretion of the Compensation Committee. For options, we set the option exercise price, and grant date fair value based on the closing price of our common stock on Nasdaq on the date of grant. The shares underlying options typically vest in four equal annual installments. For other equity awards, the grant date fair value is based on the closing price of our common stock on Nasdaq on the date of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Equity Awards</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">The following table sets forth certain information concerning our outstanding equity&nbsp;awards for our named executive officers at December 31, 2021.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>Outstanding Equity Awards At Fiscal Year-End</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="12" style="vertical-align:middle;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option Awards</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="5" style="vertical-align: bottom; width: 5%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Stock Awards</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 8.8%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5.1%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Grant </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Equity </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Award</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: bottom; width: 5.8%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number</b>&nbsp;<b>of</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Underlying</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unexercised</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(#)</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercisable (1)</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: bottom; width: 6.3%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number</b>&nbsp;<b>of</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Underlying</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unexercised</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(#)</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unexerciseable (1)</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: bottom; width: 3%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise</b>&nbsp;<b>Price</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>($)</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4.7%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration</b>&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: bottom; width: 5%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>shares or </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>units of stock</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>that have</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>not vested (#)</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: bottom; width: 5.9%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Market value</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of shares of </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>units of stock </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>that have </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>not vested ($) (3)</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:8.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp, Chairman, President - Chief Executive Officer (2)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/16/2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">223,635</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.73</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6/16/2031</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/16/2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">100,000</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">186,000</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,834</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62,500</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.56</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7/2/2030</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">44,151</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">82,121</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/11/2019</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,668</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,666</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.86</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7/11/2029</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/11/2019</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26,408</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">49,119</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/6/2018</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63,930</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">19,403</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.92</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6/6/2028</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/3/2017</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">56,667</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">14.94</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10/3/2027</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:8.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster, Chief Financial Officer and Executive Vice President</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/16/2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">108,770</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.73</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6/16/2031</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/16/2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">50,000</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">93,000</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">19,167</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">57,500</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.56</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7/2/2030</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/11/2019</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26,250</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26,250</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.86</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7/11/2029</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/6/2018</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37,626</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">12,541</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.92</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6/6/2028</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/3/2017</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">24,167</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">14.94</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10/3/2027</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/19/2016</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">66,667</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">35.10</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8/19/2026</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:8.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Donald Picker, Chief Scientific Officer</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/16/2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62,676</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.73</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6/16/2031</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2020</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,167</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">12,500</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.56</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7/2/2030</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/11/2019</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,334</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,333</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.86</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7/11/2029</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/6/2018</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9,375</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,125</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.92</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6/6/2028</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/3/2017</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,000</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">14.94</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10/3/2027</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares underlying the options vest in equal annual installments over a four-year period (i.e., one-quarter of each grant vests on the first, second, third and fourth anniversary of the grant date).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(2)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Restricted stock unit award vests in four equal annual installments, subject to continued service with us through each applicable vesting date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the closing price of our common stock on December 31, 2021&nbsp;of&nbsp;$1.86.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Employment Agreements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:9pt;"><b><i>Klemp Employment Agreement</i></b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">On October 13, 2016, we entered into an employment agreement with Mr. Walter V. Klemp pursuant to which Mr. Klemp agreed to serve as our Chief Executive Officer commencing on such date. The agreement provided for an initial annual salary of $300,000, which is reviewed annually. If Mr. Klemp&#8217;s employment is terminated at our election without &#8220;cause&#8221; (as defined in the agreement), which requires 30 days advanced notice, or by Mr. Klemp for &#8220;good reason&#8221; (as defined in the agreement), Mr. Klemp shall be entitled to receive severance payments equal to 12 months of Mr. Klemp&#8217;s base salary. Mr. Klemp has agreed not to compete with us for 12 months after the termination of his employment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Foster Employment Agreement</i></b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">On August 19, 2016, we entered into an employment agreement with Mr. Jonathan P. Foster pursuant to which Mr. Foster agreed to serve as our Chief Financial Officer and Executive Vice President commencing on such date for an initial term of three years, which is automatically renewed for additional one-year terms unless either party chooses not to renew the agreement. The agreement provided for an initial annual salary of $250,000, which is reviewed annually. Mr. Foster may receive an annual bonus, provided that the final determination on the amount of the annual bonus, if any, will be made by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Under the agreement, Mr. Foster was granted a ten-year option to purchase 66,667 shares at an exercise price per share equal to the closing price of our common stock on the date of execution of his employment agreement, which was $35.10. The option vested&nbsp;in four equal installments on each of the succeeding four anniversary dates of the execution of the agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If Mr. Foster&#8217;s employment is terminated at our election without &#8220;cause&#8221; (as defined in the agreement), which requires 90 days advance notice, or by Mr. Foster for &#8220;good reason&#8221; (as defined in the agreement), Mr. Foster shall be entitled to receive severance payments equal to nine months of Mr. Foster&#8217;s base salary and a pro rata portion of the target bonus, if any, for the year in which such termination occurs. In addition, if Mr. Foster&#8217;s employment is terminated prior to the end of the term of the agreement by us without cause or by Mr. Foster for good reason, and such termination occurs within three months prior to a change in control, in contemplation of a change in control or within six months after a change in control, Mr. Foster shall be entitled to receive, in addition to the severance discussed above, an acceleration of the vesting of the option grant described in the prior paragraph. Mr. Foster agreed not to compete with us until nine months after the termination of his employment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Director Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our compensation committee has engaged Pay Governance LLC, an independent compensation consultant, to advise them on matters relating to our non-employee director compensation program. Based on a review of a compensation study prepared by Pay Governance, our compensation committee recommended to our Board and our Board approved the following policy for compensating non-employee members of the Board:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;Each non-employee director shall receive annual cash compensation of $40,000. In addition, the chairperson of the Audit Committee, Compensation Committee and Nominating and Governance Committee shall receive an annual compensation of $15,000, $10,000 and $7,500, respectively; the other members of such committees shall receive an annual compensation of $7,500, $5,000 and $3,750, respectively; and the Lead Independent Director shall receive an annual compensation of $15,000. All payments will be made within 15 days after calendar quarter end.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;Upon the initial appointment (or election) of non-employee directors to the Board, the director will be issued a 10-year option to purchase 6,667&nbsp;shares of our common stock, under our 2015 Stock Plan, with 3-year annual vesting and an exercise price equal the closing price of our common stock on the date of the appointment (or election).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">&#8226; &nbsp;&nbsp;&nbsp;&nbsp;Annually, on the date of our annual meeting, each non-employee director that is re-elected at the annual meeting will be issued, upon a motion and approval of the Board of Directors, a 10-year option to purchase 3,334&nbsp;shares of our common stock, under our 2015 Stock Plan, with 1-year annual vesting and an exercise price equal the closing price of our common stock on the date of the annual meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:9pt;">The following table sets forth the total compensation earned by our non-employee directors in 2021 (Mr. Klemp does not earn additional compensation for his services on the Board, and his compensation is fully reflected in the &#8220;-Summary Compensation Table&#8221; above):&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:23.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees earned or paid in cash ($)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Option awards ($) (1)</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total ($)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:23.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael D. Cannon</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">76,250</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">32,902</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">109,152</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:23.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert E. George</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">82,500</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">32,902</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">115,402</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:23.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John Climaco</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">86,250</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">32,902</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">119,152</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:23.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Elizabeth Cermak</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">76,250</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">32,902</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">109,152</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents the full grant date fair value of the option award our board approved and granted to each non-employee director, calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the director. For a summary of the assumptions made in the valuation of the awards, please see Note 6 to our financial statements as of and for the period ended December 31, 2021&nbsp;included in the Form 10-K provided to you along with this proxy statement. As of December 31, 2021, the aggregate number of shares outstanding under all options to purchase our common stock held by our non-employee directors were: Mr. Cannon - 26,668&nbsp;shares; Mr. George - 26,668&nbsp;shares;&nbsp;Mr. Climaco - 24,168&nbsp;shares, and Ms. Cermak - 16,667&nbsp;shares. None of our non-employee directors held stock awards other than options as of December 31, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Securities Authorized for Issuance under Equity Compensation Plans</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The following table sets forth information regarding our equity compensation plans at December 31, 2021:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 6.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Plan category</b>&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 6.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of securities to be issued upon exercise of outstanding options, warrants and rights</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(a)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 6.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted-average exercise price of outstanding options, warrants and rights</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(b)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 6.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(c)</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equity compensation plans approved by security holders (1)</p>
			</td>
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,438,352</p>
			</td>
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8.45</p>
			</td>
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,628</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equity compensation plans not approved by security holders (2)</p>
			</td>
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">396,502</p>
			</td>
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.59</p>
			</td>
			<td style="vertical-align:top;width:6.2%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8212;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(1) Represents shares of common stock issuable upon exercise of outstanding stock options under our current 2015 Stock Plan.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">(2) Consists of warrants issued to consultants for services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Scientific Advisory Board</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our executive team is supported by our scientific advisory board, the members of which include scientists experienced in the fields in which we pursue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><i>Dr. Waldemar Priebe, Ph.D, Chair of Scientific Advisory Board (SAB)</i>. Waldemar Priebe is a founder of and one of the founding scientists at Moleculin, LLC and serves as Chairman of our Scientific Advisory Board. Dr. Priebe is also a Professor of Medicinal Chemistry at the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Priebe led the discovery of the molecules that form the basis for our lead drug candidates. As a founder or founding scientist at a number of successful biotechnology firms such as Aronex Pharmaceuticals, Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, and IntertechBio, Dr. Priebe has been integral in advancing several drugs through the pipeline, three of which are currently in clinical development. He has also developed several new small molecule compounds that have been licensed as potential drugs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><i>Dr. Jorge Cortes, M.D., SAB Member.</i> Dr. Cortes is Director of the Georgia Cancer Center at Augusta University after serving for 23 years in the Department of Leukemia at MD Anderson Cancer Center where he served as deputy chair and directed the CML and AML Programs. Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, and completed his medical oncology fellowship at MD Anderson. Dr. Cortes, whose clinical interest focuses on new drug development and the management of patients with myelodysplatic syndromes, acute and chronic leukemias, and myeloproliferative disorders has authored over 1000 peer-reviewed medical publications in top-tier journals including New England Journal of Medicine, Lancet Oncology, Lancet Hematology, Journal of Clinical Oncology, Leukemia, Blood and many others. He has authored several books and book chapters in prestigious publications such as Cancer Medicine and Harrison&#237;s Principles of Internal Medicine. He has received numerous awards including the Faculty Scholar Award from MD Anderson in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, The Dr. John J. Kenny Award from The Leukemia &amp; Lymphoma Society in 2007, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson in 2007, The Professor David Galton Lecture from the Imperial College of London Hammersmith Hospital in London, UK in 2011, the William Randolph Hearst Foundations Faculty Achievement Award in Education in 2013, and The Gerald P. Bodey Award for Excellence in Education in 2014. He is currently the Cecil F. Whitaker Jr. Georgia Research Academy Eminent Scholar Chair in Cancer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><i>Dr. James L. Abbruzzese, M.D., SAB Member. </i>Dr. Abbruzzese is the Chief of the Division of Medical Oncology at Duke University, and Member of the Duke Cancer Institute at Durham, North Carolina. Dr. Abbruzzese earned his medical degree with honors from the University of Chicago Pritzker School of Medicine and completed his residency in Internal Medicine at Johns Hopkins Hospital. He also completed clinical fellowships in Infectious Diseases at the Johns Hopkins and in Medical Oncology and Medical Oncology Research Laboratory of Neoplastic Disease Mechanisms at the Dana-Farber Cancer Institute of Harvard Medical School. Dr. Abbruzzese has spent most of his professional career at M.D. Anderson, where he rose through the ranks to his current leadership positions as Chairman of the Department of Gastrointestinal Medical Oncology and Associate Vice-Provost for Clinical Research. Among his many accomplishments, Dr. Abbruzzese is a Fellow of the American College of Physicians and Fellow of the American Society of Clinical Oncology. He has co-authored more than 400 research publications and currently serves as Chair of the Clinical Trials and Translational Research Advisory Committee of the National Cancer Institute.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><i>Dr. Hongbo Zhai, SAB Member. </i>Dr. Zhai former Senior Faculty and Supervisor of Postdoctoral Fellows at University of California San Francisco, has joined Moleculin's Science Advisory Board. Dr. Zhai has over 20 years research and development experience in pharmaceuticals and biotechnology. He has worked in oncology, dermatology and virology within China for three drug technologies. Dr. Zhai has contributed to the development of products in collaboration with global Fortune 500 companies such as Procter &amp; Gamble, Pfizer, Johnson &amp; Johnson, 3M Pharmaceuticals, and L'Oreal and has published more than 120 scientific articles in his research areas.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><i>Dr. Martin Tallman</i> - Dr. Tallman is&nbsp;a board-certified hematologist and oncologist and Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center.&nbsp;Before joining Memorial Sloan Kettering, Dr. Tallman was on the faculty of Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center for more than 20 years. There he directed the Leukemia Program, was Co-Director of the Hematologic Malignancy Program at the Robert H. Lurie Comprehensive Cancer Center, and was Associate Chief of the Division of Hematology-Oncology. Dr. Tallman completed fellowship training at the Fred Hutchinson Cancer Center and University of Washington at Seattle.&nbsp;Dr. Tallman is an Associate Editor for the journal&nbsp;<i>Blood</i>, the major periodical publishing new information regarding leukemias and other blood disorders. He is currently Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group (ECOG), one of only three large cooperative oncology groups in the US responsible for coordinating large clinical trials of new therapies for patients with all of the acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms.&nbsp;The ECOG, in collaboration with other cooperative oncology groups in the US and around the world, has carried out many important clinical trials which have set the standard of care for the most effective treatment of many of the leukemias and related disorders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;"><i>Richard Whitley, M.D.</i> -&nbsp;Richard Whitley, M.D., is a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery; Loeb Eminent Scholar Chair in Pediatrics; Co-Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Scientist, Cancer Research and Training Center; Faculty, Gene Therapy Center; Associate Director for Drug Discovery and Development and Senior Leader, Pediatric Oncology Program, O&#8217;Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB); and Co-Founder and Co-Director, Alabama Drug Discovery Alliance. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group whose role is to perform clinical trials of antiviral therapies directed against medically important viral diseases of children and adults including viruses considered as threats to human health. He has published more than 347 articles. He participates in numerous Data Safety and Monitoring Boards for ongoing clinical studies. He is a past President of the Infectious Diseases Society of America and received the UAB President&#8217;s Medal in 2007. In 2013, he was named as the inaugural recipient of the Distinguished Clinical Research Scholar and Educator in Residence at the NIH Clinical Center.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We compensate the members of our Scientific Advisory Board, or SAB, based on our utilization of their time. As of the date hereof, we have entered into compensatory agreements with Drs. Waymack, Estey, Cortes, Abbruzzese, and Tallman pursuant to which we made a one-time grant of a 10-year option to purchase 1,667&nbsp;shares of our common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting and an exercise price equal to the closing price of our common stock on the date of the grant. In addition, we agreed to pay Dr. Waymack a fee of $4,000 per month. We entered into a SAB agreement with Dr. Priebe in March 2020, as described in the "Related Party Transactions" section below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="RELATED_PARTY_TRANSACTIONS" name="RELATED PARTY TRANSACTIONS" title="RELATED PARTY TRANSACTIONS"></a>RELATED PARTY TRANSACTIONS</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In connection with the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC two agreements with Houston Pharmaceuticals, Inc. ("HPI"). Waldemar Priebe is a shareholder&nbsp;of HPI, and Dr. Priebe's spouse has the voting and dispositive power over our shares held by HPI. Under the first agreement, HPI&#8217;s option to obtain an exclusive sublicense was terminated in exchange for a payment of $100,000 and the issuance of 104,834 shares of our common stock, valued at $36 per share. Under the second agreement (HPI Out-Licensing Agreement), HPI received a non-exclusive technology rights and development sublicense under which it continued its ongoing work to develop the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling $750,000 over a three-year period. Of this amount, all has been paid as of December 31, 2021. We expensed such costs as incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. Pursuant to the HPI Out-Licensing Agreement, we had the right within three years of the effective date to buy-out from HPI all rights granted to HPI under the agreement for a payment of $1.0 million. The option repurchase payment was paid on April 30, 2019 for $1.0 million and, accordingly, the HPI Out-Licensing Agreement was terminated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In August 2019, we entered into a sublease with HPI, pursuant to which we granted HPI access to our lab space in exchange for HPI agreeing to pay us 50% of the rent payable under our lease for such lab space. In March 2020, we entered into an agreement with HPI pursuant to which we were permitted to utilize the lab equipment owned or leased by HPI that is located in our lab space in exchange for paying $15,000 to HPI each quarter plus a one-time payment of $20,000. In March 2020, we entered into a consulting agreement, which is terminable on ten days&#8217; notice by either party, with HPI pursuant to which HPI will continue to assist us with research and development. Pursuant to the consulting agreement, we made a one-time payment to HPI of $50,000 and we&nbsp;pay HPI $43,500 per quarter for services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In March 2020, we entered into a scientific advisory board member agreement with Dr. Priebe pursuant to which we agreed to pay Dr. Priebe an annual amount of $68,500.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In August 2021, we entered into a portfolio development advisory agreement with an entity affiliated with Dr. Priebe. In connection with the services to be provided pursuant to the agreement, we agreed to issue the entity a ten-year warrant to purchase 250,000 shares of our common stock with an exercise price of $3.08, which was equal to the market price of our common stock on the effective date of the agreement. The warrant vest as follows: (a) 50% vests upon execution of the agreement, provided the advisor does not terminate the agreement prior to the end of the one-year term; and (b) 50% vests 60 days after the end of the one-year term, subject to our Board of Directors determining that the services to be provided have been adequately performed; provided that the warrant shall vest in full upon a change of control event.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We currently employ Lindsay Picker, the daughter of Donald Picker, our president and chief operating officer, as a clinical research associate&nbsp;on an at-will basis at an annual salary of $82,512.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In February 2019, we entered into sublicense agreements with WPD Pharmaceuticals, Inc. and Animal Lifesciences, LLC. Dr. Priebe is affiliated with both WPD Pharmaceuticals, Inc. and Animal Lifesciences, LLC. For more information on the terms of these agreements, please see Item 1 - Business-Our Licensing Agreements in the Form 10-K you received along with this proxy statement. In addition, Dr. Picker and Dr. Silberman have in the past&nbsp;performed consulting work for WPD Pharmaceuticals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In August 2018, CNS Pharmaceuticals, Inc. entered into sublicense agreements with WPD Pharmaceuticals, Inc. and Animal Lifesciences, LLC pursuant to which CNS Pharmaceuticals, Inc. licensed the rights to their lead drug candidate, Berubicin, an anthracycline. Mr. Climaco is the chief executive officer of CNS Pharmaceuticals, Inc. and Drs. Picker and Silberman are the part-time chief science officer and chief medical officer for CNS Pharmaceuticals, Inc. In addition, Dr. Picker was previously a director of CNS Pharmaceuticals, Inc. Dr. Priebe is the founder of CNS Pharmaceuticals, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and bylaws. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at our request. We believe that these charter provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may decline in value to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Policies and Procedures for Related Party Transactions</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our audit committee charter provides that our audit committee is responsible for reviewing and approving in advance any related party transaction. This will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or will be a participant to, where the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person.&nbsp;In determining whether to approve a proposed transaction, our audit committee will consider all relevant facts and circumstances including: (i) the materiality and character of the related party&#8217;s direct or indirect interest; (ii) the commercial reasonableness of the terms; (iii) the benefit or perceived benefit, or lack thereof, to us; (iv) the opportunity cost of alternate transactions; and (v) the actual or apparent conflict of interest of the related party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><a id="PROPOSAL_1:_ELECTION_OF_DIRECTORS" name="PROPOSAL 1: ELECTION OF DIRECTORS" title="PROPOSAL 1: ELECTION OF DIRECTORS"></a><b>PROPOSAL 1:</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b>ELECTION OF DIRECTORS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Board of Directors currently consists of six members: Walter V. Klemp, Robert George, John Climaco, Michael Cannon, Elizabeth Cermak, and Joy Yan. The Nominating and Governance Committee nominated and the Board approved and recommended all of the current members of our Board for re-election. All nominees have consented to being named herein and have indicated their intention to serve as our directors, if elected. The Board has no reason to believe that any nominee would be unable or unwilling to serve if elected. Unless authority to do so is withheld, the persons named as proxies will vote the shares represented by such proxies for the election of the named director nominees. In case any of the nominees becomes unavailable for election to the Board the persons named as proxies will have full discretion and authority to vote or refrain from voting for any other nominees in accordance with their judgment. The Board nominees, if elected, will serve until the next annual meeting of shareholders or until each successor is duly elected and qualified.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Biographical information for our directors is provided above in the section entitled &#8220;Information About Directors and Executive Officers.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Vote Required and Recommendation of the Board of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">A plurality of the eligible votes cast is required to elect director nominees, and as such, the six nominees who receive the greatest number of votes cast by stockholders, entitled to vote at the meeting, will be elected. A nominee who receives a plurality means he or she has received more votes than any other nominee for the same director&#8217;s seat. Broker non-votes will have no effect on this proposal. <b>The Board recommends that stockholders vote FOR each of the six</b>&nbsp;<b>nominees for election to our Board of Directors.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="PROPOSAL_2:_TO_RATIFY_THE_APPOINTMENT_OF_INDEPENDENT_REGISTERED_PUBLIC_" name="PROPOSAL 2: TO RATIFY THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC " title="PROPOSAL 2: TO RATIFY THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC "></a>PROPOSAL 2:</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>TO RATIFY THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Audit Committee has selected Grant Thornton LLP as our independent registered public accounting firm to audit our financial statements for the fiscal year ending December&nbsp;31, 2022. Our stockholders are being asked to ratify this appointment. In the event that ratification of this selection of auditors is not approved by the stockholders, we will reassess our selection of auditors. Representatives of Grant Thornton LLP are expected to be present at the Annual Meeting, will be available to respond to appropriate questions, and will have the opportunity to make a statement at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Aggregate fees for professional services rendered by Grant Thornton, LLP for their services for the fiscal years ended December&nbsp;31, 2021&nbsp;and 2020, respectively, were as follows:</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:38.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2020</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:38.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Audit Fees</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">352,450</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">325,200</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:38.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Audit-related fees</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:5.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:5.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:38.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tax fees</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:5.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:5.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:38.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All other fees</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:38.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TOTAL</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">352,450</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">325,200</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Audit Fees</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Audit fees represent the aggregate fees billed for professional services rendered by our independent accounting firm for the audit of our annual financial statements, review of financial statements included in our quarterly reports, review of registration statements or services that are normally provided in connection with statutory and regulatory filings or engagements for those fiscal years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Audit-Related Fees</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Audit-related fees represent the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit Fees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Tax Fees</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Tax fees represent the aggregate fees billed for professional services rendered by our principal accountants for tax compliance, tax advice, and tax planning for such years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>All Other Fees</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">All other fees represent the aggregate fees billed for products and services other than the services reported in the other categories.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Audit Committee Pre-Approval Policies and Procedures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Audit Committee on an annual basis reviews audit and non-audit services performed by the independent auditors. All audit and non-audit services are pre-approved by the Audit Committee, which considers, among other things, the possible effect of the performance of such services on the auditors&#8217; independence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Vote Required and Recommendation of the Board of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 2 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal. <b>The Board recommends that stockholders vote FOR the ratification of the appointment of Grant Thornton, LLP as our independent registered public accounting firm for the fiscal year ending December</b>&nbsp;<b>31, 2022.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="AUDIT_COMMITTEE_REPORT" name="AUDIT COMMITTEE REPORT" title="AUDIT COMMITTEE REPORT"></a>AUDIT COMMITTEE REPORT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Audit Committee assists the Board of Directors with its oversight responsibilities regarding the Company&#8217;s financial reporting process. The Company&#8217;s management is responsible for the preparation, presentation and integrity of the Company&#8217;s financial statements and the reporting process, including the Company&#8217;s accounting policies, internal control over financial reporting and disclosure controls and procedures. Grant Thornton LLP, the Company&#8217;s independent registered public accounting firm, is responsible for performing an audit of the Company&#8217;s financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We have reviewed and discussed with management and Grant Thornton LLP the Company&#8217;s audited financial statements. We discussed with Grant Thornton LLP the overall scope and plans of their audit. We met with Grant Thornton LLP, with and without management present, to discuss the results of its examinations, its evaluation of the Company&#8217;s internal controls, and the overall quality of the Company&#8217;s financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">With regard to the fiscal year ended December 31, 2021, the Audit Committee (i) reviewed and discussed with management the Company&#8217;s audited financial statements as of December 31, 2021, and for the year then ended; (ii) discussed with Grant Thornton LLP the matters required by Public Company Accounting Oversight Board (PCAOB) and the Securities and Exchange Commission;&nbsp;(iii) received the written disclosures and the letter from Grant Thornton LLP required by applicable requirements of the PCAOB regarding Grant Thornton LLP&#8217;s communications with the Audit Committee regarding independence; and (iv) discussed with Grant Thornton LLP their independence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Based on the review and discussions described above, the Audit Committee recommended to the Company&#8217;s Board of Directors that the Company&#8217;s audited financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, for filing with the Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Robert George (Chairperson)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Michael Cannon</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">John Climaco</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Elizabeth Cermak</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><a id="PROPOSAL_3:_TO_APPROVE_AN_INCREASE_IN_THE_NUMBER_OF_SHARES_OF_COMMON_STOCK_AUTHORIZED_FOR_ISSUANCE_UNDER_THE_2015_PLAN." name="PROPOSAL 3: TO APPROVE AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2015 PLAN." title="PROPOSAL 3: TO APPROVE AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2015 PLAN."></a>PROPOSAL 3: TO APPROVE AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2015 STOCK PLAN.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In March 2022, the compensation committee of the Board approved an amendment to the Moleculin Biotech, Inc. 2015 Stock Plan (the &#8220;2015 Plan&#8221;) to increase the number of shares of common stock authorized for issuance under the 2015 Plan by 2,000,000 shares. This share increase requires stockholder approval, which the Company is seeking at this stockholders&#8217; meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The 2015 Plan was originally adopted by our Board and stockholders in connection with our initial public offering and became effective in December 2015. Equity awards have been historically and, we believe, will continue to be, an integral component of our overall compensation program for our employees, directors and consultants. Approval of the share increase will allow us to continue to grant equity awards at levels we determine to be appropriate in order to attract new employees and directors, retain our existing employees and directors and to provide incentives for such persons to exert maximum efforts for our success. The share increase will allow us to continue to utilize a broad array of equity incentives with flexibility in designing equity incentives, including stock option grants, stock appreciation rights, stock awards, and stock unit awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We believe it is critical for our long-term success that the interests of our employees and directors are tied to our success as &#8220;owners&#8221; of our business. The equity incentive programs we have in place are intended to build stockholder value by attracting and retaining talented employees and directors. We believe we must continue to offer competitive equity compensation packages in order to retain and motivate the talent necessary for our continued growth and success. We carefully monitor the equity compensation and equity holdings of our employees, directors and consultants as well as the type of equity awards we grant to ensure these awards continue to provide incentives for the recipients to work towards our success. To date, stock options and restricted stock units have been the sole component of our equity program. The potential value of stock options is realized only if our share price increases, and so stock options provide a strong incentive for individuals to work to build stockholder value.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">As of the Record Date, we had 19,961&nbsp;shares remaining available for grant under the 2015 Plan. There are a total of 1,460,019&nbsp;stock awards outstanding with a weighted average exercise price of $8.35&nbsp;per share. We have and we expect to continue to experience growth in personnel as we progress our business and advance our drug candidates through clinical trials. If our stockholders do not approve the amendment to 2015 Plan, as amended, we believe that we will be unable to successfully use equity as part of our compensation program, as most of our competitors in the industry do, putting us at a significant disadvantage. Therefore, we believe that approval of this request is in the best interest of our stockholders and our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Key Features Designed to Protect Stockholders</b>&#8217;<b> Interests</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The design of the 2015 Plan reflects our commitment to corporate governance and the desire to preserve stockholder value as demonstrated by the following features of the plan:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Independent administrator</u>. The compensation committee of the board of directors, which is comprised solely of non-employee directors, administers the 2015 Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>No evergreen feature</u>. The maximum number of shares available for issuance under the 2015 Plan is fixed and cannot be increased without stockholder approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Repricing prohibited</u>. Stockholder approval is required for any repricing of any stock options or stock appreciation rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Limitations on Dividend Payments on Awards</u>. Dividends and dividend equivalents on all stock units and stock awards are paid only to the extent the awards vest, and no dividends or dividend equivalents are ever paid on stock options or stock appreciation rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>No discount awards; maximum term specified</u>. Stock options and stock appreciation rights must have an exercise price or base price no less than the fair market value on the date the award is granted and a term no longer than ten years&#8217; duration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Award design flexibility</u>. Different kinds of awards may be granted under the 2015 Plan, giving us the flexibility to design our equity incentives to compliment the other elements of compensation and to support the attainment of our strategic goals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Share counting</u>. The number of shares available for grant under the 2015 Plan is reduced by the gross number of shares subject to awards, and shares withheld for taxes in connection with awards or tendered in payment of an option&#8217;s exercise price cannot be used for future grants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Non-employee director limits</u>. The 2015 Plan contains a limit on the compensation that may be paid to any non-employee member of our Board in any calendar year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>No tax gross-ups</u>. The 2015 Plan does not provide for tax gross-ups.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><u>Fixed term</u>. The 2015 Plan has a fixed term of ten years from its initial effective date, or December 1, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Description of the 2015 Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The 2015 Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards, stock unit awards and stock appreciation rights to key employees, non-employee directors and consultants. The material features of the 2015 Plan are outlined below. The following description of the 2015 Plan is a summary only and is qualified in its entirety by reference to the complete text of the 2015 Plan. Stockholders are urged to read the actual text of the 2015 Plan in its entirety, which is appended to this Proxy Statement as <u>Annex B</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Administration</i></b><b>.</b>&nbsp;The 2015 Plan is administered by our compensation committee of the board of directors (we refer to the body administering the 2015 Plan as the "Committee"). The Committee, which is comprised of directors who satisfy the non-employee director definition under Rule 16b-3 of the Securities Exchange Act of 1934,&nbsp;has full authority to select the individuals who will receive awards under the 2015 Plan, determine the form and amount of each of the awards to be granted and establish the terms and conditions of awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Limit on Non-Employee Director Compensation. </i></b>Under the 2015 Plan, the following limits apply to non-employee directors. The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a non-employee director with respect to any calendar year, including awards granted under the 2015 Plan and cash fees paid to such non-employee director, will not exceed $300,000 in total value. For purposes of these limitations, the value of awards is calculated based on the grant date fair value of such awards for financial reporting purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Number of Shares of Common Stock.</i></b>&nbsp;As of the Record Date, 19,961&nbsp;shares remain available for issuance under the 2015 Plan, which currently provides for up to 1,750,001&nbsp;shares to be issued. If this proposal is approved, the number of shares of the common stock that may be issued under the 2015 Plan will be 3,750,000 (this includes the 2,000,000 share increase being requested in this proxy statement), of which 2,019,961&nbsp;shares will be available for future issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Shares issuable under the 2015 Plan may be authorized but unissued shares or treasury shares. If there is a lapse, forfeiture, expiration, termination or cancellation of any award made under the Amended 2015 Plan for any reason, the shares subject to the award will again be available for issuance. Any shares subject to an award that are delivered to us by a participant, or withheld by us on behalf of a participant, as payment for an award or payment of withholding taxes due in connection with an award will not again be available for issuance, and all such shares will count toward the number of shares issued under the 2015 Plan. The number of shares of common stock issuable under the 2015 Plan is subject to adjustment, in the event of any reorganization, recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off, combination, subdivision, consolidation or exchange of shares, any change in the capital structure of the company or any similar corporate transaction. In each case, the Committee has the discretion to make adjustments it deems necessary to preserve the intended benefits under the 2015 Plan. No award granted under the 2015 Plan may be transferred, except by will, the laws of descent and distribution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Eligibility</i></b><b>.</b>&nbsp;All employees designated as key employees for purposes of the 2015 Plan, all non-employee directors and consultants are eligible to receive awards under the 2015 Plan. As of March 28, 2022, 19&nbsp;employees and all&nbsp;6&nbsp;non-employee directors were eligible to participate in the 2015 Plan.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Awards to Participants</i></b><b>.</b>&nbsp;The 2015 Plan provides for discretionary awards of stock options, stock awards, stock unit awards and stock appreciation rights to participants. Each award made under the 2015 Plan will be evidenced by a written award agreement specifying the terms and conditions of the award as determined by the Committee in its sole discretion, consistent with the terms of the 2015 Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Stock Options</i>.&nbsp;The Committee has the discretion to grant non-qualified stock options or incentive stock options to participants and to set the terms and conditions applicable to the options, including the type of option, the number of shares subject to the option and the vesting schedule; provided that the exercise price of each stock option will be the closing price of the common stock on the date on which the option is granted ("fair market value"), each option will expire ten years from the date of grant and no dividend equivalents may be paid with respect to stock options.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In addition, an incentive stock option granted to a key employee is subject to the following rules: (i) the aggregate fair market value (determined at the time the option is granted) of the shares of common stock with respect to which incentive stock options are exercisable for the first time by a key employee during any calendar year (under all incentive stock option plans of the company and its subsidiaries) cannot exceed $100,000, and if this limitation is exceeded, that portion of the incentive stock option that does not exceed the applicable dollar limit will be an incentive stock option and the remainder will be a non-qualified stock option; (ii) if an incentive stock option is granted to a key employee who owns stock possessing more than 10% of the total combined voting power of all class of stock of the company, the exercise price of the incentive stock option will be 110% of the closing price of the common stock on the date of grant and the incentive stock option will expire no later than five years from the date of grant; and (iii) no incentive stock option can be granted after ten years from the initial effective date of the 2015 Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Stock Appreciation Rights.</i><b><i> </i></b>The Committee has the discretion to grant stock appreciation rights to participants. The Committee determines the exercise price for a stock appreciation right, which cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the exercise of a stock appreciation right, we will pay the participant in common stock or in cash, at our discretion, an amount equal to the product of (1) the excess of the per share fair market value of our common stock on the date of exercise over the exercise price, multiplied by (2) the number of shares of common stock with respect to which the stock appreciation right is exercised. The Committee has the discretion to set the terms and conditions applicable to the award, including the number of shares subject to the stock appreciation right and the vesting schedule, provided that each stock appreciation right will expire not more than ten years from the date of grant and no dividends or dividend equivalents shall be paid with respect to any stock appreciation right prior to the exercise of the stock appreciation right.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Stock Awards</i>.&nbsp;The Committee has the discretion to grant stock awards to participants. Stock awards will consist of shares of common stock granted without any consideration from the participant or shares sold to the participant for appropriate consideration as determined by the Board. The number of shares awarded to each participant, and the restrictions, terms and conditions of the award, will be at the discretion of the Committee. Subject to the restrictions, a participant will be a shareholder with respect to the shares awarded to him or her and will have the rights of a shareholder with respect to the shares, including the right to vote the shares and receive dividends on the shares; provided that dividends otherwise payable on any stock award subject to restrictions will be held by us and will be paid to the holder of the stock award only to the extent the restrictions on such stock award lapse.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><i>Stock Units.</i>&nbsp;The Committee has the discretion to grant stock unit awards to participants. Each stock unit entitles the participant to receive, on a specified date or event set forth in the award agreement, one share of common stock or cash equal to the fair market value of one share on such date or event, as provided in the award agreement. The number of stock units awarded to each participant, and the terms and conditions of the award, will be at the discretion of the Committee. Unless otherwise specified in the award agreement, a participant will not be a shareholder with respect to the stock units awarded to him prior to the date they are settled in shares of common stock. The award agreement may provide that until the restrictions on the stock units lapse, the participant will be paid an amount equal to the dividends that would have been paid had the stock units been actual shares; provided that such dividend equivalents will be held by us and paid only to the extent the restrictions lapse.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Payment for Stock Options and Withholding Taxes</i></b><b>.</b>&nbsp;The Committee may make one or more of the following methods available for payment of any award, including the exercise price of a stock option, and for payment of the tax obligation associated with an award: (i) cash; (ii) cash received from a broker-dealer to whom the holder has submitted an exercise notice together with irrevocable instructions to deliver promptly to us the amount of sales proceeds from the sale of the shares subject to the award to pay the exercise price or withholding tax; (iii) by directing us to withhold shares of common stock otherwise issuable in connection with the award having a fair market value equal to the amount required to be withheld; and (iv) by delivery of previously acquired shares of common stock that are acceptable to the Committee and that have an aggregate fair market value on the date of exercise equal to the exercise price or withholding tax, or certification of ownership by attestation of such previously acquired shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Provisions Relating to a "Change in Control" of the Company</i></b><b>.</b>&nbsp;Notwithstanding any other provision of the 2015 Plan or any award agreement, in the event of a "Change in Control" of the company, the Committee has the discretion to provide that all outstanding awards will become fully exercisable, all restrictions applicable to all awards will terminate or lapse, and performance goals applicable to any stock awards will be deemed satisfied at the target level. In addition, upon such Change in Control, the Committee has sole discretion to provide for the purchase of any outstanding stock option for cash equal to the difference between the exercise price and the then fair market value of the common stock subject to the option had the option been currently exercisable, make such adjustment to any award then outstanding as the Committee deems appropriate to reflect such Change in Control and cause any such award then outstanding to be assumed by the acquiring or surviving corporation after such Change in Control.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Amendment of Award Agreements; Amendment and Termination of the Amended 2015 Plan; Term of the 2015 Plan</i></b><b>.</b>&nbsp;The Committee may amend any award agreement at any time, provided that no amendment may adversely affect the right of any participant under any agreement in any material way without the written consent of the participant, unless such amendment is required by applicable law, regulation or stock exchange rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The Board may terminate, suspend or amend the 2015 Plan, in whole or in part, from time to time, without the approval of the stockholders, unless such approval is required by applicable law, regulation or stock exchange rule, and provided that no amendment may adversely affect the right of any participant under any outstanding award in any material way without the written consent of the participant, unless such amendment is required by applicable law, regulation or rule of any stock exchange on which the shares are listed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Notwithstanding the foregoing, neither the 2015 Plan nor any outstanding award agreement can be amended in a way that results in the repricing of a stock option. Repricing is broadly defined to include reducing the exercise price of a stock option or stock appreciation right or cancelling a stock option or stock appreciation right in exchange for cash, other stock options or stock appreciation rights with a lower exercise price or other stock awards. (This prohibition on repricing without stockholder approval does not apply in case of an equitable adjustment to the awards to reflect changes in the capital structure of the company or similar events.)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">No awards may be granted under the 2015 Plan on or after the tenth anniversary of the initial effective date of the 2015 Plan, or December 1, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>U.S. Federal Income Tax Consequences</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The information set forth below is a summary only and does not purport to be complete. The information is based upon current U.S. federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any recipient of an award may depend on his or her particular situation, each recipient should consult the recipient&#8217;s tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an award or the disposition of shares acquired as a result of an award. The 2015 Plan will not be qualified under the provisions of section 401(a) of the Code and will not be subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Non-Qualified Stock Options</i></b>. A participant will not recognize any income at the time of grant. On the date the participant exercises the non-qualified stock option, the participant will recognize ordinary income in an amount equal to the excess of the fair market value of the shares on the date of exercise over the exercise price. The participant will be responsible for remitting to us the withholding tax obligation that arises at the time the option is exercised. We generally will receive a tax deduction for the same amount of ordinary income recognized by the participant. When the participant sells these shares, any gain or loss recognized by the participant is treated as either short-term or long-term capital gain or loss depending on whether the participant has held the shares more than one year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Incentive Stock Options.</i></b> A participant will not recognize any income at the time of grant. If the participant is issued shares pursuant to the exercise of an incentive stock option, and if the participant does not make a disqualifying disposition of the shares within one year after the date of exercise or within two years after the date of grant, the participant will not recognize any income, for federal income tax purposes, at the time of the exercise. When the participant sells the shares issued pursuant to the incentive stock option, the participant will be taxed, for federal income tax purposes, as a long-term capital gain on any amount recognized by the participant in excess of the exercise price, and any loss sustained by the participant will be a long-term capital loss. No deduction will be allowed to us for federal income tax purposes. If, however, the participant sells the shares before the expiration of the holding periods, the participant will recognize ordinary income on the difference between the exercise price and the fair market value at exercise, and we generally will receive a tax deduction in the same amount. Upon exercise of an incentive stock option, the excess of the fair market value over the exercise price is an item of tax preference to the participant for purposes of determining the alternative minimum tax.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In order to qualify as an incentive stock option, the option must be exercised within three months after the participant&#8217;s termination of employment for any reason other than death or disability and within one year after termination of the participant&#8217;s employment due to disability. If the option is not exercised within this time period, it will be treated as a non-qualified stock option and taxed accordingly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Stock Awards/Stock Units.</i></b> If a participant receives a stock award, the participant will recognize ordinary income upon becoming entitled to transfer the shares at the end of the restriction period without forfeiture. A participant generally will recognize ordinary income when he receives cash or shares pursuant to the settlement of stock units, provided that if the shares are subject to any further restrictions on transfer, the participant will recognize ordinary income upon becoming entitled to transfer the shares at the end of the restriction period without forfeiture. The amount of income the participant recognizes will be equal to the fair market value of the shares on such date, or the amount of cash received less the amount paid by the participant for the shares. This amount will also be the participant&#8217;s tax basis for the shares. The participant will be responsible for remitting to us the withholding tax obligation that arises at the time the ordinary income is recognized. In addition, the holding period begins on the day the restrictions lapse, or the date the shares are received if not subject to any restrictions, for purposes of determining whether the participant has long-term or short-term capital gain or loss on a subsequent sale of the shares. We generally will be entitled to a deduction with respect to the ordinary income recognized by the participant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If a participant who receives a stock award subject to restrictions makes an election under Section 83(b) of the Code within 30 days after the date of the grant, the participant will have ordinary income equal to the fair market value on the date of grant, less the amount paid by the participant for the shares, and the participant will recognize no additional income until the participant subsequently sells the shares. The participant will be responsible for remitting to us the withholding tax obligation that arises at the time the ordinary income is recognized. When the participant sells the shares, the tax basis will be equal to the fair market value on the date of grant and the holding period for capital gains purposes begins on the date of the grant. If the participant forfeits the shares subject to the Section 83(b) election, the participant will not be entitled to any deduction, refund, or loss for tax purposes (other than a capital loss with respect to the amount previously paid by the participant), and we will have to include the amount that was previously deducted from our gross income in the taxable year of the forfeiture.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b><i>Stock Appreciation Rights</i></b>. A participant will not recognize any income at the time of the grant of a stock appreciation right. Upon exercise of the stock appreciation right, the participant will recognize ordinary income equal to the amount received upon exercise. The participant will be responsible for remitting to us the withholding tax obligation that arises at the time the ordinary income is recognized. We generally will be entitled to a deduction with respect to the ordinary income recognized by the participant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Awards Granted Under the 2015 Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 13pt;text-indent:36pt;">The following awards have been granted under the Plan:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><u>Name and Position</u></p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><u>Number of Units</u></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Walter V. Klemp, Chairman, President - Chief Executive Officer</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">530,303&nbsp;Stock Options</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:33.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">211,687&nbsp;Restricted Stock Units</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Jonathan P. Foster, CFO &amp; Executive Vice President</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">378,938&nbsp;Stock Options</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:33.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp; &nbsp; &nbsp; 50,000 Restricted Stock Units</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Donald Picker, Chief Scientific Officer</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">118,510 Stock Options</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Executive Group:</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">1,032,752&nbsp;Stock Options</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Executive Director Group:</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp; &nbsp; &nbsp; 100,838 Stock Options</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:33.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Non-Executive Officer Employee Group:</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">135,003&nbsp;Stock Options</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">It is not possible at this time to determine the specific awards that will be made in the future under the 2015 Plan. On March 28, 2022, the last reported sales price for the common stock was $1.72&nbsp;per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Vote Required and Recommendation of the Board of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 3 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal. <b>The Board recommends that stockholders vote FOR the approval of the share increase under the Company</b>&#8217;<b>s 2015 Stock Plan.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><a id="PROPOSAL_4:_TO_VOTE_ON_A_NON-BINDING,_ADVISORY_RESOLUTION_TO_APPROVE_EXECUTIVE_COMPENSATION" name="PROPOSAL 4: TO VOTE ON A NON-BINDING, ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION" title="PROPOSAL 4: TO VOTE ON A NON-BINDING, ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION"></a>PROPOSAL 4:</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>TO VOTE ON A NON-BINDING, ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">As required by Section 951 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section 14A of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our Board is requesting stockholders to vote, on a non-binding advisory basis, to approve the compensation paid to our named executive officers, as disclosed in this proxy statement. This proposal, commonly known as a &#8220;say-on-pay&#8221; proposal, gives stockholders the opportunity to express their views on the compensation of our named executive officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and our executive compensation philosophy, policies and practices described in this proxy statement. The overall compensation of our named executive officers subject to the vote is disclosed in this proxy statement in the subsections entitled &#8220;Executive Officer Compensation,&#8221; &#8220;Narrative to Summary Compensation Table,&#8221; &#8220;Equity Awards,&#8221; and &#8220;Employment Agreements&#8221; in the section entitled &#8220;Compensation Of Directors And Executive Officers&#8221; above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Compensation Committee continually reviews our executive compensation program to determine whether such program achieves our desired goals of aligning our executive compensation strategy and structure with our stockholders&#8217; interests and current market practices. Our executive compensation strategy and structure is designed to motivate our executive management team to create long-term value for our stockholders through the achievement of strategic business objectives, while effectively managing the risks and challenges inherent in a clinical and pre-clinical stage biopharmaceutical company. As our long-term success depends on the talents of our employees, our compensation structure plays a significant role in our ability to attract, retain and motivate the highest quality workforce in a competitive employment environment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Advisory Vote</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">We recommend stockholder approval of the compensation of our named executive officers for the 2021 fiscal year as disclosed in this proxy statement pursuant to the SEC&#8217;s compensation disclosure rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Accordingly, the Board recommends that stockholders vote in favor of the following resolution:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:18pt;">&#8220;RESOLVED, that the compensation paid to Moleculin&#8217;s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion is hereby APPROVED.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">As this is an advisory vote, the outcome of the vote is non-binding on us with respect to future executive compensation decisions, including those related to our named executive officers. However, our Board and Compensation Committee will review the results of the vote and take them into account when considering future executive compensation policies and decisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If Proposal 5 is approved, unless the Board modifies its policy on the frequency of future advisory votes on the compensation of our named executive officers, the next advisory vote on the compensation of our named executive officers will be held at our next annual meeting of stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Vote Required and Recommendation of the Board of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 4 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal. <b>The Board recommends that stockholders vote FOR the</b> <b>non-binding, advisory resolution to approve executive compensation.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><a id="PROPOSAL_5:_TO_VOTE_ON_A_NON-BINDING,_ADVISORY_PROPOSAL_ON_THE_FREQUENCY_OF_HOLDING_FUTURE_VOTES_REGARDING_EXECUTIVE_COMPENSATION" name="PROPOSAL 5: TO VOTE ON A NON-BINDING, ADVISORY PROPOSAL ON THE FREQUENCY OF HOLDING FUTURE VOTES REGARDING EXECUTIVE COMPENSATION" title="PROPOSAL 5: TO VOTE ON A NON-BINDING, ADVISORY PROPOSAL ON THE FREQUENCY OF HOLDING FUTURE VOTES REGARDING EXECUTIVE COMPENSATION"></a>PROPOSAL 5:</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>TO VOTE ON A NON-BINDING, ADVISORY PROPOSAL ON THE FREQUENCY OF HOLDING FUTURE VOTES REGARDING EXECUTIVE COMPENSATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Pursuant to Section 14A of the Exchange Act, we are required to provide our stockholders with the opportunity to vote, on a non-binding, advisory basis, for their preference as to how frequently to hold future votes to approve, on a nonbinding, advisory basis, the compensation of our named executive officers, which we refer to as the &#8220;say-on-pay vote&#8221;). Stockholders may indicate whether they would prefer that we conduct future say-on-pay votes once every one, two, or three years. Stockholders also may abstain from casting a vote on this proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Board of Directors has determined that an advisory vote on executive compensation every year&nbsp;will permit our stockholders to provide direct input on our executive compensation philosophy, policies, and practices as disclosed in this proxy statement, on a regular basis. This approach is consistent with our efforts to engage in an ongoing dialogue with our stockholders on executive compensation and corporate governance matters. An advisory vote on executive compensation occurring every year&nbsp;will provide our stockholders the opportunity to provide the next advisory vote on executive compensation at our next&nbsp;Annual Meeting of Stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">This vote is advisory, which means that the vote on executive compensation is not binding on the company, our Board of Directors, or the Compensation Committee of the Board of Directors. We recognize that stockholders may have different views as to the best approach for the Company, and therefore we look forward to hearing from our stockholders as to their preferences on the frequency of an advisory vote on executive compensation. Our Board of Directors and Compensation Committee will take into account the outcome of the vote; however, when considering the frequency of future say-on-pay votes, our Board of Directors may decide that it is in the best interests of our stockholders and the Company to hold future say-on-pay votes more or less frequently than the frequency receiving the most votes cast by our stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Vote Required and Recommendation of the Board of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 5 requires the affirmative vote of a majority of the shares present in person or by proxy and entitled to vote on the matter. Broker non-votes will not be taken into account in determining the outcome of the proposal, and abstentions will be counted as votes against the proposal. <b>The Board recommends that stockholders vote FOR the</b> <b>option of a vote every year as the preferred frequency for future say-on-pay votes.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><a id="PROPOSAL_6:_TO_APPROVE_AN_AMENDMENT_TO_THE_COMPANY'S_AMENDED_AND_RESTATED_CERTIFICATE_OF_INCORPORATION_TO_ELIMINATE_SUPERMAJORITY_VOTING_REQUIREMENTS_TO_AMEND_THE_AMENDED_AND_RESTATED_CERTIFICATE_OF_INCORPORATION" name="PROPOSAL 6: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING REQUIREMENTS TO AMEND THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION" title="PROPOSAL 6: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING REQUIREMENTS TO AMEND THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION"></a>PROPOSAL 6:</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING REQUIREMENTS TO AMEND THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Introduction and Reasons for Amendments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Article 8 of our amended and restated certificate of incorporation currently provides that certain amendments to the amended and restated certificate of incorporation require the affirmative vote of two-thirds of the voting power of the shares of the Company entitled to vote generally in the election of directors. Our Board of Directors has determined that it is advisable and in our best interests and our stockholders to amend the amended and restated certificate of incorporation to eliminate this supermajority voting requirement. We believe that these proposed amendment reflect our commitment to good corporate governance and further aligns our governance processes with practices supported by stockholders in the broader investor community who generally view a majority vote as sufficient for stockholder approval of amendments to governing documents. As a result, we recommend and are seeking stockholder approval of this Proposal 6.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Background on the Proposed Amendment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Article 8 of the amended and restated certificate of incorporation provides that, in addition to any affirmative vote required by applicable law or the terms of any series of preferred stock outstanding, the affirmative vote of the holders of not less than two-thirds of the voting power of all then outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter or repeal, or adopt any provision as part of the amended and restated certificate of incorporation inconsistent with the purpose and intent of the sections of the amended and restated certificate of incorporation regarding:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number, term of, and election of directors (Article 5);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope of our ability to provide indemnification and the advancement of expenses to our directors and officers (Article 6);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the limitation of liability of our directors for certain actions (Article 7);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability to amend the amended and restated certificate of incorporation (Article 8);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our election to be governed by Section 203 of the Delaware General Corporation Law (Article 9); and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:6.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our stockholders ability to act by written consent (Article 10).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Overview and Effects of the Proposed Amendment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If Proposal 6 is approved by stockholders, the voting standard set forth in the Delaware General Corporation Law would apply, which would mean that future amendments to the Certificate of Incorporation would require the affirmative vote of the holders of at least a majority of the shares of common stock entitled to vote thereon, voting together as a single class (subject to any other provisions of the amended and restated certificate of incorporation, any other vote required by law and the express terms of any outstanding preferred stock). Annex A to this proxy statement shows the changes to the amended and restated certificate of incorporation that would be effected by this Proposal 6, if adopted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If our stockholders approve Proposal 6, then, subject to applicable law, they will become effective immediately upon the Company&#8217;s filing of an amended and restated certificate of incorporation with the Delaware Secretary of State, which we anticipate doing as soon as practicable following stockholder approval of Proposal 6. If stockholders do not approve Proposal 6, the supermajority voting requirements will remain in place, and the Company will not file the anticipated amended and restated certificate of incorporation with the Delaware Secretary of State.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Vote Required and Recommendation of the Board of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The approval of Proposal 6 requires the affirmative vote of two-thirds of our outstanding shares entitled to vote on the matter. Broker non-votes and abstentions will be counted as votes against the proposal. <b>The Board recommends that stockholders vote FOR the</b>&nbsp;<b>approval of the amendment to the Company's amended and restated certificate of incorporation to eliminate supermajority voting requirements to amend the amended and restated certificate of incorporation.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="AVAILABILITY_OF_ANNUAL_REPORT_ON_FORM_10-K" name="AVAILABILITY OF ANNUAL REPORT ON FORM 10-K" title="AVAILABILITY OF ANNUAL REPORT ON FORM 10-K"></a>AVAILABILITY OF ANNUAL REPORT ON FORM 10-K</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>A copy of our 2021</b>&nbsp;<b>Annual Report on Form 10-K has been mailed concurrently with this proxy statement to stockholders entitled to notice of and to vote at the Annual Meeting, provided that we have not included the exhibits to the Form 10-K. We will provide copies of these exhibits without cost upon request by eligible stockholders. Requests for copies of such exhibits should be mailed to Moleculin Biotech,</b>&nbsp;<b>Inc., 5300 Memorial Drive, Suite 950, Houston, TX 77007, Attention: Corporate Secretary.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><a id="OTHER_PROPOSED_ACTION" name="OTHER PROPOSED ACTION" title="OTHER PROPOSED ACTION"></a><b>OTHER PROPOSED ACTION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Our Board of Directors does not intend to bring any other matters before the Annual Meeting, nor does it know of any matters which other persons intend to bring before the Annual Meeting. If, however, other matters not mentioned in this proxy statement properly come before the Annual Meeting, the persons named in the accompanying form of proxy will vote thereon in accordance with the recommendation of the Board of Directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="HOUSEHOLDING_OF_PROXY_MATERIALS" name="HOUSEHOLDING OF PROXY MATERIALS" title="HOUSEHOLDING OF PROXY MATERIALS"></a>HOUSEHOLDING OF PROXY MATERIALS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">A number of brokers with account holders who are the Company&#8217;s stockholders may be &#8220;householding&#8221; our proxy materials. A single copy of the proxy materials may be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate copy of the proxy materials, please (1) notify your broker, or (2) direct your written request to Moleculin Biotech, Inc., 5300 Memorial Drive, Suite 950, Houston, TX 77007, Attention: Corporate Secretary. Stockholders who currently receive multiple copies of the proxy materials at their address and would like to request householding of their communications should contact their brokers. In addition, upon written request to the address set forth above, we will promptly deliver a separate copy of the proxy materials to any stockholder at a shared address to which a single copy of the documents was delivered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt;"><b><a id="STOCKHOLDER_PROPOSALS_AND_SUBMISSIONS" name="STOCKHOLDER PROPOSALS AND SUBMISSIONS" title="STOCKHOLDER PROPOSALS AND SUBMISSIONS"></a>STOCKHOLDER PROPOSALS AND SUBMISSIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">In order to be eligible for inclusion in our proxy statement and form of proxy for our next Annual Meeting, a proposal of a stockholder, including the submission of a stockholder nominee for election to our Board of Directors, must be received at our principal executive offices located in Houston, Texas no later than December 14,&nbsp;2022. For any proposal that a stockholder wishes to propose for consideration at our next Annual Meeting but does not wish to include in the proxy materials for that meeting, our Amended and Restated Bylaws require a notice of the proposal to be delivered not less than 120 days prior to the anniversary of the mailing date of our proxy materials for the preceding annual meeting of stockholders. The notice of the proposal also must comply with the content requirements for such notices set forth in our Amended and Restated Bylaws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Whether or not you expect to be present at the Annual Meeting, please sign and return the enclosed proxy promptly. Your vote is important. If you are a stockholder of record and attend the Annual Meeting and wish to vote in person, you may withdraw your proxy at any time prior to the vote.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:30.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By Order of the Board of Directors</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MOLECULIN BIOTECH,&nbsp;INC.</p>
			</td>
			<td style="vertical-align:bottom;width:19.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:30.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:19.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:30.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>/s/ WALTER V. KLEMP</u></p>
			</td>
			<td style="vertical-align:bottom;width:19.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:30.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp</p>
			</td>
			<td style="vertical-align:bottom;width:19.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:30.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board, President and Chief Executive Officer</p>
			</td>
			<td style="vertical-align:bottom;width:19.9%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Houston, Texas</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">April 14, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><a id="Annex_A" name="Annex A" title="Annex A"></a>Annex A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>TEXT OF PROPOSED AMENDMENT TO THE CERTIFICATE OF INCORPORATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:27pt;">The proposed amendment to the amended and restated certificate of incorporation would amend Sections 8 thereof as follows, with new language indicated by underlined text and deletions indicated by strikethroughs:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:27pt;">Article 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AMENDMENT OF CERTIFICATE</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:27pt;">The Corporation reserves the right to amend, alter or repeal any provision contained in this certificate of incorporation in the manner prescribed by the DGCL and all rights conferred upon stockholders are granted subject to this reservation. <strike>Notwithstanding any other provision of this certificate of incorporation, and in addition to any other vote that may be required by law or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter or repeal, or adopt any provision as part of this certificate of incorporation inconsistent with the purpose and intent of Articles 5, 6, 7, 8, 9 or 10.</strike>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: right;"><b><a id="Annex_B" name="Annex B" title="Annex B"></a>Annex B</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>MOLECULIN BIOTECH, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2015 STOCK PLAN</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>(Amended and Restated)</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Establishment and Purpose.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">1.1&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors of Moleculin Biotech, Inc. (the &#8220;Company&#8221;) established the Moleculin Biotech, Inc. 2015 Stock Plan (the &#8220;Plan&#8221;) effective as of December 1, 2015. The Plan was amended effective as of April 19, 2016, was further amended and restated effective as of April 6, 2018, was further amended and restated as of March 26, 2020, and was further amended and restated as of April 7, 2022, subject to approval by the Company&#8217;s stockholders at the Company&#8217;s annual meeting on May 26, 2022. Awards granted prior to the effective date of the Plan&#8217;s amendment and restatement shall be governed by the terms of the Plan as in effect on the grant date of the Award.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">1.2&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Plan is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and Consultants, and to provide such Key Employees, Directors and Consultants with additional incentive to expand and improve the profits and achieve the objectives of the Company and its Subsidiaries, by providing such Key Employees, Directors and Consultants with the opportunity to acquire or increase their proprietary interest in the Company through receipt of Awards.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Definitions.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As used in the Plan, the following terms shall have the meanings set forth below:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.1&nbsp; &nbsp; &nbsp; &#8220;<u>Award</u>&#8221; means any award or benefit granted under the Plan, which shall be a Stock Option, a Stock Award, a Stock Unit Award or an SAR.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.2&nbsp; &nbsp; &nbsp; &#8220;<u>Award Agreement</u>&#8221; means, as applicable, a Stock Option Agreement, Stock Award Agreement, Stock Unit Award Agreement or SAR Agreement evidencing an Award granted under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.3&nbsp; &nbsp; &nbsp; &#8220;<u>Board</u>&#8221; means the Board of Directors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.4&nbsp; &nbsp; &nbsp; &#8220;<u>Change in Control</u>&#8221; has the meaning set forth in Section 8.2 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.5&nbsp; &nbsp; &nbsp; &#8220;<u>Code</u>&#8221; means the Internal Revenue Code of 1986, as amended from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.6&nbsp; &nbsp; &nbsp; &#8220;<u>Committee</u>&#8221; means the Compensation Committee of the Board or such other committee as may be designated by the Board from time to time to administer the Plan, or, if no such committee has been designated at the time of any grants, it shall mean the Board.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.7&nbsp; &nbsp; &nbsp; &#8220;<u>Common Stock</u>&#8221; means the Common Stock, par value $0.001 per share, of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.8&nbsp; &nbsp; &nbsp; &#8220;<u>Company</u>&#8221; means Moleculin Biotech, Inc., a Delaware corporation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.9&nbsp; &nbsp; &nbsp; &#8220;<u>Consultant</u>&#8221; means any person, including an advisor, who is engaged by the Company or an affiliate to render consulting or advisory services and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.10&nbsp; &nbsp; &#8220;<u>Director</u>&#8221; means a director of the Company who is not an employee of the Company or a Subsidiary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.11&nbsp; &nbsp; &#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.12&nbsp; &nbsp; &#8220;<u>Fair Market Value</u>&#8221; means as of any date, the closing price of a share of Common Stock on the national securities exchange on which the Common Stock is listed, or, if the Common Stock is not listed on a national securities exchange, the over-the-counter market on which the Common Stock trades, or, if the Common Stock is not listed on a national securities exchange or an over-the-counter market, as determined by the Board as of such date, or, if no trading occurred on such date, as of the trading day immediately preceding such date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.13&nbsp; &nbsp; &#8220;<u>Incentive Stock Option</u>&#8221; or &#8220;<u>ISO</u>&#8221; means a Stock Option granted under Section 5 of the Plan that meets the requirements of Section 422(b) of the Code or any successor provision.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.14&nbsp; &nbsp; &#8220;<u>Key Employee</u>&#8221; means an employee of the Company or any Subsidiary selected to participate in the Plan in accordance with Section 3. A Key Employee may also include a person who is granted an Award (other than an Incentive Stock Option) in connection with the hiring of the person prior to the date the person becomes an employee of the Company or any Subsidiary, provided that such Award shall not vest prior to the commencement of employment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.15&nbsp; &nbsp; &#8220;<u>Non-Qualified Stock Option</u>&#8221; or &#8220;<u>NSO</u>&#8221; means a Stock Option granted under Section 5 of the Plan that is not an Incentive Stock Option.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.16&nbsp; &nbsp; &#8220;<u>Participant</u>&#8221; means a Key Employee, Director or Consultant selected to receive an Award under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.17&nbsp; &nbsp; &#8220;<u>Plan</u>&#8221; means the Moleculin Biotech, Inc. 2015 Stock Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.18&nbsp; &nbsp; &#8220;<u>Stock Appreciation Right</u>&#8221; or &#8220;<u>SAR</u>&#8221; means a grant of a right to receive shares of Common Stock or cash under Section 8 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.19&nbsp; &nbsp; &#8220;<u>Stock Award</u>&#8221; means a grant of shares of Common Stock under Section 6 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.20&nbsp; &nbsp; &#8220;<u>Stock Option</u>&#8221; means an Incentive Stock Option or a Non-Qualified Stock Option granted under Section 5 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.21&nbsp; &nbsp; &#8220;<u>Stock Unit Award</u>&#8221; means a grant of a right to receive shares of Common Stock or cash under Section 7 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.22&nbsp; &nbsp; &#8220;<u>Subsidiary</u>&#8221; means an entity of which the Company is the direct or indirect beneficial owner of not less than 50% of all issued and outstanding equity interest of such entity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt; text-align: justify;"><b>Administration.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>The Board</u>.<u> </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Plan shall be administered by the Committee, which shall be comprised of at least two members of the Board who satisfy the &#8220;non-employee director&#8221; definition set forth in Rule 16b-3 under the Exchange Act, unless the Board otherwise determines.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Authority of the Committee</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Committee, in its sole discretion, shall determine the Key Employees and Directors to whom, and the time or times at which Awards will be granted, the form and amount of each Award, the expiration date of each Award, the time or times within which the Awards may be exercised, the cancellation of the Awards and the other limitations, restrictions, terms and conditions applicable to the grant of the Awards. The terms and conditions of the Awards need not be the same with respect to each Participant or with respect to each Award.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;To the extent permitted by applicable law, regulation, and rules of a stock exchange on which the Common Stock is listed or traded, the Committee may delegate its authority to grant Awards to Key Employees and to determine the terms and conditions thereof to such officer of the Company as it may determine in its discretion, on such terms and conditions as it may impose, except with respect to Awards to officers subject to Section 16 of the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Committee may, subject to the provisions of the Plan, establish such rules and regulations as it deems necessary or advisable for the proper administration of the Plan, and may make determinations and may take such other action in connection with or in relation to the Plan as it deems necessary or advisable. Each determination or other action made or taken pursuant to the Plan, including interpretation of the Plan and the specific terms and conditions of the Awards granted hereunder, shall be final and conclusive for all purposes and upon all persons.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;No member of the Board or the Committee shall be liable for any action taken or determination made hereunder in good faith. Service on the Committee shall constitute service as a Director so that the members of the Committee shall be entitled to indemnification and reimbursement as Directors of the Company pursuant to the Company&#8217;s Certificate of Incorporation and By-Laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.3&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Award Agreements</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Award shall be evidenced by a written Award Agreement specifying the terms and conditions of the Award. In the sole discretion of the Committee, the Award Agreement may condition the grant of an Award upon the Participant&#8217;s entering into one or more of the following agreements with the Company: (i) an agreement not to compete with the Company and its Subsidiaries which shall become effective as of the date of the grant of the Award and remain in effect for a specified period of time following termination of the Participant&#8217;s employment with the Company; (ii) an agreement to cancel any employment agreement, fringe benefit or compensation arrangement in effect between the Company and the Participant; and (iii) an agreement to retain the confidentiality of certain information. Such agreements may contain such other terms and conditions as the Committee shall determine. If the Participant shall fail to enter into any such agreement at the request of the Committee, then the Award granted or to be granted to such Participant shall be forfeited and cancelled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Shares of Common Stock Subject to Plan.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Total Number of Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The total number of shares of Common Stock that may be issued under the Plan shall be 3,750,000 (which reflects the 1,750,000 shares previously authorized under the Plan and 2,000,000 shares to be issued under the Plan pursuant to this amendment and restatement). Such shares may be either authorized but unissued shares or treasury shares, and shall be adjusted in accordance with the provisions of Section 4.3 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of Common Stock delivered by a Participant or withheld by the Company on behalf of any such Participant as full or partial payment of an Award, including the exercise price of a Stock Option or of any required withholding taxes, shall not again be available for issuance pursuant to subsequent Awards, and shall count towards the aggregate number of shares of Common Stock that may be issued under the Plan. Any shares of Common Stock purchased by the Company with proceeds from a Stock Option exercise shall not again be available for issuance pursuant to subsequent Awards, shall count against the aggregate number of shares that may be issued under the Plan and shall not increase the number of shares available under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;If there is a lapse, forfeiture, expiration, termination or cancellation of any Award for any reason (including for reasons described in Section 3.3), or if shares of Common Stock are issued under such Award and thereafter are reacquired by the Company pursuant to rights reserved by the Company upon issuance thereof, the shares of Common Stock subject to such Award or reacquired by the Company shall again be available for issuance pursuant to subsequent Awards, and shall not count towards the aggregate number of shares of Common Stock that may be issued under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Shares Under Awards</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Of the shares of Common Stock authorized for issuance under the Plan pursuant to Section 4.1:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Common Stock as to which a Key Employee may receive Stock Options or SARs in any calendar year is 225,000, except that the maximum number of shares of Common Stock as to which a Key Employee may receive Stock Options or SARs in the calendar year in which such Key Employee begins employment with the Company or its Subsidiaries is 225,000.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Common Stock that may be subject to Stock Options (ISOs and/or NSOs) is 3,750,000.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Common Stock that may be used for Stock Awards and/or Stock Unit Awards that may be granted to any Key Employee in any calendar year is 225,000, or, in the event the Award is settled in cash, an amount equal to the Fair Market Value of such number of shares on the date on which the Award is settled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Common Stock subject to Awards granted under the Plan or otherwise during any one calendar year to any Director, taken together with any cash fees paid by the Company to such Director during such calendar year for service on the Board, will not exceed $300,000 in total value (calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The numbers of shares described herein shall be as adjusted in accordance with Section 4.3 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.3&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Adjustment</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event of any reorganization, recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off, combination, subdivision, consolidation or exchange of shares, any change in the capital structure of the Company or any similar corporate transaction, the Committee shall make such adjustments as it deems appropriate, in its sole discretion, to preserve the benefits or intended benefits of the Plan and Awards granted under the Plan. Such adjustments may include: (a) adjustment in the number and kind of shares reserved for issuance under the Plan; (b) adjustment in the number and kind of shares covered by outstanding Awards; (c) adjustment in the exercise price of outstanding Stock Options or SARs or the price of Stock Awards or Stock Unit Awards under the Plan; (d) adjustments to any of the shares limitations set forth in Section 4.1 or 4.2 of the Plan; and (e) any other changes that the Committee determines to be equitable under the circumstances.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Grants of Stock Options.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Grant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Subject to the terms of the Plan, the Committee may from time to time grant Stock Options to Participants. Unless otherwise expressly provided at the time of the grant, Stock Options granted under the Plan to Key Employees will be NSOs. Stock Options granted under the Plan to Directors who are not employees of the Company or any Subsidiary will be NSOs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Stock Option Agreement</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The grant of each Stock Option shall be evidenced by a written Stock Option Agreement specifying the type of Stock Option granted, the exercise period, the exercise price, the terms for payment of the exercise price, the expiration date of the Stock Option, the number of shares of Common Stock to be subject to each Stock Option and such other terms and conditions established by the Committee, in its sole discretion, not inconsistent with the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.3&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Exercise Price and Exercise Period</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">With respect to each Stock Option granted to a Participant:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The per share exercise price of each Stock Option shall be the Fair Market Value of the Common Stock subject to the Stock Option on the date on which the Stock Option is granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Stock Option shall become exercisable as provided in the Stock Option Agreement; provided that the Committee shall have the discretion to accelerate the date as of which any Stock Option shall become exercisable in the event of the Participant&#8217;s termination of employment with the Company, or service on the Board, without cause (as determined by the Board in its sole discretion).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;No dividends or dividend equivalents shall be paid with respect to any shares subject to a Stock Option prior to the exercise of the Stock Option.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Each Stock Option shall expire, and all rights to purchase shares of Common Stock thereunder shall expire, on the date ten years after the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.4&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Required Terms and Conditions of ISOs</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to the foregoing, each ISO granted to a Key Employee shall be subject to the following specific rules:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The aggregate Fair Market Value (determined with respect to each ISO at the time such Option is granted) of the shares of Common Stock with respect to which ISOs are exercisable for the first time by a Key Employee during any calendar year (under all incentive stock option plans of the Company and its Subsidiaries) shall not exceed $100,000. If the aggregate Fair Market Value (determined at the time of grant) of the Common Stock subject to an ISO which first becomes exercisable in any calendar year exceeds the limitation of this Section 5.4(a), so much of the ISO that does not exceed the applicable dollar limit shall be an ISO and the remainder shall be a NSO; but in all other respects, the original Stock Option Agreement shall remain in full force and effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, if an ISO is granted to a Key Employee who owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (or its parent or subsidiaries within the meaning of Section 422(b)(6) of the Code): (i) the purchase price of each share of Common Stock subject to the ISO shall be not less than 110% of the Fair Market Value of the Common Stock on the date the ISO is granted; and (ii) the ISO shall expire, and all rights to purchase shares of Common Stock thereunder shall expire, no later than the fifth anniversary of the date the ISO was granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;No ISOs shall be granted under the Plan after ten years from the earlier of the date the Plan is adopted or approved by shareholders of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.5&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Exercise of Stock Options</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;A Participant entitled to exercise a Stock Option may do so by delivering written notice to that effect specifying the number of shares of Common Stock with respect to which the Stock Option is being exercised and any other information the Committee may prescribe. All notices or requests provided for herein shall be delivered to the Chief Financial Officer of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Committee in its sole discretion may make available one or more of the following alternatives for the payment of the Stock Option exercise price: (i) in cash; (ii) in cash received from a broker-dealer to whom the Participant has submitted an exercise notice together with irrevocable instructions to deliver promptly to the Company the amount of sales proceeds from the sale of the shares subject to the Stock Option to pay the exercise price; (iii) by directing the Company to withhold such number of shares of Common Stock otherwise issuable in connection with the exercise of the Stock Option having an aggregate Fair Market Value equal to the exercise price; (iv) by delivering previously acquired shares of Common Stock that are acceptable to the Committee and that have an aggregate Fair Market Value on the date of exercise equal to the Stock Option exercise price; or (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The Committee shall have the sole discretion to establish the terms and conditions applicable to any alternative made available for payment of the Stock Option exercise price.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 38pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Stock Awards.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">6.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Grant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Committee may, in its discretion, (a) grant shares of Common Stock under the Plan to any Participant without consideration from such Participant or (b) sell shares of Common Stock under the Plan to any Participant for such amount of cash, Common Stock or other consideration as the Committee deems appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">6.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Stock Award Agreement</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Each share of Common Stock granted or sold hereunder shall be subject to such restrictions, conditions and other terms as the Board may determine at the time of grant or sale, the general provisions of the Plan, the restrictions, terms and conditions of the related Stock Award Agreement, and the following specific rules:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Award Agreement shall specify whether the shares of Common Stock are granted or sold to the Participant and such other provisions, not inconsistent with the terms and conditions of the Plan, as the Committee shall determine.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The restrictions to which the shares of Common Stock awarded hereunder are subject shall lapse as provided in Stock Award Agreement; provided that the Committee shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award held by a Participant in the event of the Participant&#8217;s termination of employment with the Company, or service on the Board, without cause (as determined by the Committee in its sole discretion).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in this subsection (c) and unless otherwise set forth in the related Stock Award Agreement, the Participant receiving a grant of or purchasing Common Stock shall thereupon be a stockholder with respect to such shares and shall have the rights of a stockholder with respect to such shares, including the right to vote such shares and to receive dividends and other distributions paid with respect to such shares; provided that any dividends or other distributions payable with respect to the Stock Award shall be accumulated and held by the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with the terms of the applicable Stock Award Agreement. Any such dividends or other distributions held by the Company attributable to the portion of a Stock Award that is forfeited shall also be forfeited.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Stock Unit Awards.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">7.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Grant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Committee may, in its discretion, grant Stock Unit Awards to any Participant. Each Stock Unit subject to the Award shall entitle the Participant to receive, on the date or the occurrence of an event (including the attainment of performance goals) as described in the Stock Unit Award Agreement, a share of Common Stock or cash equal to the Fair Market Value of a share of Common Stock on the date of such event as provided in the Stock Unit Award Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">7.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Stock Unit Agreement</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Each Stock Unit Award shall be subject to such restrictions, conditions and other terms as the Committee may determine at the time of grant, the general provisions of the Plan, the restrictions, terms and conditions of the related Stock Unit Award Agreement and the following specific rules:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Stock Unit Agreement shall specify such provisions, not inconsistent with the terms and conditions of the Plan, as the Committee shall determine.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The restrictions to which the shares of Stock Units awarded hereunder are subject shall lapse as provided in Stock Unit Agreement; provided that the Committee shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award held by a Participant in the event of the Participant&#8217;s termination of employment with the Company, or service on the Board, without cause (as determined by the Board in its sole discretion).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in this subsection (c) and unless otherwise set forth in the Stock Unit Agreement, the Participant receiving a Stock Unit Award shall have no rights of a stockholder, including voting or dividends or other distributions rights, with respect to any Stock Units prior to the date they are settled in shares of Common Stock; provided that a Stock Unit Award Agreement may provide that until the Stock Units are settled in shares or cash, the Participant shall be entitled to receive on each dividend or distribution payment date applicable to the Common Stock an amount equal to the dividends or other distributions that the Participant would have received had the Stock Units held by the Participant as of the related record date been actual shares of Common Stock. Such amounts shall be accumulated and held by the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with the terms of the applicable Stock Unit Award Agreement. Such amounts held by the Company attributable to the portion of the Stock Unit Award that is forfeited shall also be forfeited.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SARs.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">8.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Grant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Committee may grant SARs to Participants. Upon exercise, an SAR entitles the Participant to receive from the Company the number of shares of Common Stock having an aggregate Fair Market Value equal to the excess of the Fair Market Value of one share as of the date on which the SAR is exercised over the exercise price, multiplied by the number of shares with respect to which the SAR is being exercised. The Committee, in its discretion, shall be entitled to cause the Company to elect to settle any part or all of its obligations arising out of the exercise of an SAR by the payment of cash in lieu of all or part of the shares it would otherwise be obligated to deliver in an amount equal to the Fair Market Value of such shares on the date of exercise. Cash shall be delivered in lieu of any fractional shares. The terms and conditions of any such Award shall be determined at the time of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">8.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>SAR Agreement</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each SAR shall be evidenced by a written SAR Agreement specifying the terms and conditions of the SAR as the Committee may determine, including the SAR exercise price, expiration date of the SAR, the number of shares of Common Stock to which the SAR pertains, the form of settlement and such other terms and conditions established by the Committee, in its sole discretion, not inconsistent with the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The per Share exercise price of each SAR shall not be less than 100% of the Fair Market Value of a Share on the date the SAR is granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each SAR shall expire and all rights thereunder shall cease on the date fixed by the Committee in the related SAR Agreement, which shall not be later than the ten years after the date of grant; provided however, if a Participant is unable to exercise an SAR because trading in the Common Stock is prohibited by law or the Company&#8217;s insider-trading policy, the SAR exercise date shall be extended to the date that is 30 days after the expiration of the trading prohibition.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Each SAR shall become exercisable as provided in the related SAR Agreement; provided that notwithstanding any other Plan provision, the Committee shall have the discretion to accelerate the date as of which any SAR shall become exercisable in the event of the Participant&#8217;s termination of employment, or service on the Board, without cause (as determined by the Committee in its sole discretion).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;No dividends or dividend equivalents shall be paid with respect to any SAR prior to the exercise of the SAR.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;A person entitled to exercise an SAR may do so by delivery of a written notice in accordance with procedures established by the Committee specifying the number of shares of Common Stock with respect to which the SAR is being exercised and any other information the Committee may prescribe. As soon as reasonably practicable after the exercise of an SAR, the Company shall (i) issue the total number of full shares of Common Stock to which the Participant is entitled and cash in an amount equal to the Fair Market Value, as of the date of exercise, of any resulting fractional share, and (ii) if the Committee causes the Company to elect to settle all or part of its obligations arising out of the exercise of the SAR in cash, deliver to the Participant an amount in cash equal to the Fair Market Value, as of the date of exercise, of the shares it would otherwise be obligated to deliver.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Change in Control.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">9.1&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Effect of a Change in Control</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any of the provisions of the Plan or any outstanding Award Agreement, upon a Change in Control of the Company (as defined in Section 9.2), the Board is authorized and has sole discretion to provide that (i) all outstanding Awards shall become fully exercisable, (ii) all restrictions applicable to all Awards shall terminate or lapse and (iii) performance goals applicable to any Awards shall be deemed satisfied at the highest level, as applicable, in order that Participants may realize the benefits thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;In addition to the Board&#8217;s authority set forth in Section 3, upon such Change in Control of the Company, the Board is authorized and has sole discretion as to any Award, either at the time such Award is granted hereunder or any time thereafter, to take any one or more of the following actions: (i) provide for the purchase of any outstanding Stock Option, for an amount of cash equal to the difference between the exercise price and the then Fair Market Value of the Common Stock covered thereby had such Stock Option been currently exercisable; (ii) make such adjustment to any such Award then outstanding as the Board deems appropriate to reflect such Change in Control; and (iii) cause any such Award then outstanding to be assumed by the acquiring or surviving corporation after such Change in Control.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">9.2&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Definition of Change in Control</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#8220;Change in Control&#8221; of the Company shall be deemed to have occurred if at any time during the term of an Award granted under the Plan any of the following events occurs:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;any Person (other than the Company, a trustee or other fiduciary holding securities under an employee benefit plan of the Company, or a corporation owned directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of shares of Common Stock of the Company) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 30% or more of the combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally in the election of directors (&#8220;Person&#8221; and &#8220;Beneficial Owner&#8221; being defined in Rule 13d-3 of the General Rules and Regulations of the Exchange Act);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company is party to a merger, consolidation, reorganization or other similar transaction with another corporation or other Person unless, following such transaction, more than 50% of the combined voting power of the outstanding securities of the surviving, resulting or acquiring corporation or Person or its parent entity entitled to vote generally in the election of directors (or Persons performing similar functions) is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners of the Company&#8217;s outstanding securities entitled to vote generally in the election of directors immediately prior to such transaction, in substantially the same proportions as their ownership, immediately prior to such transaction, of the Company&#8217;s outstanding securities entitled to vote generally in the election of directors;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;the election to the Board, without the recommendation or approval of two-thirds of the incumbent Board, of the lesser of: (i) three Directors; or (ii) Directors constituting a majority of the number of Directors of the Company then in office; provided, however, that Directors whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of Directors of the Company will not be considered as incumbent members of the Board for purposes of this Section; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;there is a complete liquidation or dissolution of the Company, or the Company sells all or substantially all of its business and/or assets to another corporation or other Person unless, following such sale, more than 50% of the combined voting power of the outstanding securities of the acquiring corporation or Person or its parent entity entitled to vote generally in the election of directors (or Persons performing similar functions) is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners of the Company&#8217;s outstanding securities entitled to vote generally in the election of directors immediately prior to such sale, in substantially the same proportions as their ownership, immediately prior to such sale, of the Company&#8217;s outstanding securities entitled to vote generally in the election of directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In no event, however, shall a Change in Control be deemed to have occurred, with respect to a Participant, if that Participant is part of a purchasing group which consummates the Change in Control transaction. A Participant shall be deemed &#8220;part of a purchasing group&#8221; for purposes of the preceding sentence if the Participant is an equity participant or has agreed to become an equity participant in the purchasing company or group (except for (a) passive ownership of less than 3% of the shares of the purchasing company; or (b) ownership of equity participation in the purchasing company or group which is otherwise not deemed to be significant, as determined prior to the Change in Control by a majority of the disinterested Directors).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Payment of Taxes.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;In connection with any Award, and as a condition to the issuance or delivery of any shares of Common Stock to the Participant in connection therewith, the Company shall require the Participant to pay the Company the minimum amount of federal, state, local or foreign taxes required to be withheld, and in the Company&#8217;s sole discretion, the Company may permit the Participant to pay the Company up to the maximum individual statutory rate of applicable withholding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company in its sole discretion may make available one or more of the following alternatives for the payment of such taxes: (i) in cash; (ii) in cash received from a broker-dealer to whom the Participant has submitted notice together with irrevocable instructions to deliver promptly to the Company the amount of sales proceeds from the sale of the shares subject to the Award to pay the withholding taxes; (iii) by directing the Company to withhold such number of shares of Common Stock otherwise issuable in connection with the Award having an aggregate Fair Market Value equal to the minimum amount of tax required to be withheld; (iv) by delivering previously acquired shares of Common Stock of the Company that are acceptable to the Board that have an aggregate Fair Market Value equal to the amount required to be withheld; or (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Committee shall have the sole discretion to establish the terms and conditions applicable to any alternative made available for payment of the required withholding taxes.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Postponement.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Committee may postpone any grant or settlement of an Award or exercise of a Stock Option or SAR for such time as the Board in its sole discretion may deem necessary in order to permit the Company:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;to effect, amend or maintain any necessary registration of the Plan or the shares of Common Stock issuable pursuant to an Award, including upon the exercise of a Stock Option or SAR, under the Securities Act of 1933, as amended, or the securities laws of any applicable jurisdiction;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;to permit any action to be taken in order to (i) list such shares of Common Stock on a stock exchange if shares of Common Stock are then listed on such exchange or (ii) comply with restrictions or regulations incident to the maintenance of a public market for its shares of Common Stock, including any rules or regulations of any stock exchange on which the shares of Common Stock are listed; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;to determine that such shares of Common Stock and the Plan are exempt from such registration or that no action of the kind referred to in (b)(ii) above needs to be taken; and the Company shall not be obligated by virtue of any terms and conditions of any Award or any provision of the Plan to sell or issue shares of Common Stock in violation of the Securities Act of 1933 or the law of any government having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any such postponement shall not extend the term of an Award and neither the Company nor its Directors or officers shall have any obligation or liability to a Participant, the Participant&#8217;s successor or any other person with respect to any shares of Common Stock as to which the Award shall lapse because of such postponement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Nontransferability.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Awards granted under the Plan, and any rights and privileges pertaining thereto, may not be transferred, assigned, pledged or hypothecated in any manner, or be subject to execution, attachment or similar process, by operation of law or otherwise, other than by will or by the laws of descent and distribution.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Delivery of Shares.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Shares of Common Stock issued pursuant to a Stock Award, the exercise of a Stock or SAR or the settlement of a Stock Unit Award shall be represented by stock certificates or on a non-certificated basis, with the ownership of such shares by the Participant evidenced solely by book entry in the records of the Company&#8217;s transfer agent; provided, however, that upon the written request of the Participant, the Company shall issue, in the name of the Participant, stock certificates representing such shares of Common Stock.&nbsp; Notwithstanding the foregoing, shares granted pursuant to a Stock Award shall be held by the Secretary of the Company until such time as the shares are forfeited or settled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Termination or Amendment of Plan and Award Agreements.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">14.1&nbsp; &nbsp; &nbsp;<u>Termination or Amendment of Plan</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as described in Section 14.3 below, the Board may terminate, suspend, or amend the Plan, in whole or in part, from time to time, without the approval of the stockholders of the Company, unless such approval is required by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed. No amendment or termination of the Plan shall adversely affect the right of any Participant under any outstanding Award in any material way without the written consent of the Participant, unless such amendment or termination is required by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed. Subject to the foregoing, the Committee may correct any defect or supply an omission or reconcile any inconsistency in the Plan or in any Award granted hereunder in the manner and to the extent it shall deem desirable, in its sole discretion, to effectuate the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Board shall have the authority to amend the Plan to the extent necessary or appropriate to comply with applicable law, regulation or accounting rules in order to permit Participants who are located outside of the United States to participate in the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">14.2&nbsp; &nbsp; &nbsp;<u>Amendment of Award Agreements</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Committee shall have the authority to amend any Award Agreement at any time; provided however, that no such amendment shall adversely affect the right of any Participant under any outstanding Award Agreement in any material way without the written consent of the Participant, unless such amendment is required by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">14.3&nbsp; &nbsp; &nbsp;<u>No Repricing of Stock Options</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Notwithstanding the foregoing, and except as described in Section 4.3, there shall be no amendment to the Plan or any outstanding Stock Option Agreement or SAR Agreement that results in the repricing of Stock Options or SARs without stockholder approval. For this purpose, repricing includes (i) a reduction in the exercise price of the Stock Option or SARs or (ii) the cancellation of a Stock Option in exchange for cash, Stock Options or SARs with an exercise price less than the exercise price of the cancelled Options or SARs, other Awards or any other consideration provided by the Company, but does not include any adjustment described in Section 4.3.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 15.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>No Contract of Employment.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Neither the adoption of the Plan nor the grant of any Award under the Plan shall be deemed to obligate the Company or any Subsidiary to continue the employment of any Participant for any particular period, nor shall the granting of an Award constitute a request or consent to postpone the retirement date of any Participant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 16.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Applicable Law.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">All questions pertaining to the validity, construction and administration of the Plan and all Awards granted under the Plan shall be determined in conformity with the laws of the State of Delaware, without regard to the conflict of law provisions of any state, and, in the case of Incentive Stock Options, Section 422 of the Code and regulations issued thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="text-align: justify; margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Section 17.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Effective Date and Term of Plan.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">17.1&nbsp; &nbsp; &nbsp;<u>Effective Date</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Plan as amended and restated has been adopted by the Board, and is effective, as of March 26, 2020, subject to the approval of the Plan by the stockholders of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 30pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event the Plan is not approved by stockholders of the Company within 12 months of the date hereof, the Plan as amended and restated shall have no effect, and the Plan as in effect prior to March 26, 2020 shall continue.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">17.2&nbsp; &nbsp; &nbsp;<u>Term of Plan</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Notwithstanding anything to the contrary contained herein, no Awards shall be granted on or after December 1, 2025.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="mbrx20220406_def14aimg001.jpg" src="mbrx20220406_def14aimg001.jpg" style="width:776;height:1000;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="33" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="mbrx20220406_def14aimg002.jpg" src="mbrx20220406_def14aimg002.jpg" style="width:774;height:1001;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="34" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>mbrx20220406_def14aimg001.jpg
<TEXT>
begin 644 mbrx20220406_def14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /H P@# 2(  A$! Q$!_\0
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M6B@!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_ '1^5&U?[H_*EHH
M3:O]T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH :RKM/
MRCIZ44K?=/THH %^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ44-]T_2B@ 7[H^E
M+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!&^Z?I10WW3]** !?NCZ4M(OW1]*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** $;[I^E%#?=/THH %^Z/I2TB_='TI: "BBB@
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M%% !1110 4444 %%%% "-]T_2BAONGZ44 "_='TI:1?NCZ4M !1110 4444
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M_&F2?V6[>8[(2K?>!/!R1U^I-.>UM_(6.:X^8'<7+ '/3/M4*:7 "RBY)0@
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M8K<TZS>U\[[7<HSF,J1YF2@+,?Y$?E42:9=201/]H5W*L"ZR' ;(PP]>!^M
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MX=*D@62(GS/D9S_RS)'4_P![KS0!RUS\/9YHY!%J @,K2-,L0*B7<X95;!Z
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M)_&MFB@"D+5VL8H&VY7&<G/3^M54TR94CPT:,B[./_0OJ.U:]% &;:6$ELR
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MDG:03GMS0!':VFH02B:>[#PF-Q(S294G VG^=0PZ7? 6P4P-#:E7A4,?O?Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&&11&HW;=P.9.6''TP/SK6H **** "BBB@ HHHH **** $;[I^E%#?=/THH
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MH?#9Y;."#Z9Q^=7+N_,%M;2*L3-)*L;$GA">O3T-97]M&^BC)M8@HD#C+;@
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M]>XQ43:\\);?92LW)50 3P 67Z@']*FCU=WTR.[>T\IGD6-1(0 -V,$GTYH
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MC.>@JN?&>I&/4+I;6U^RVU@E[&I+;VWCY5/...:UI_[%N%\B^L(2EIN2(%.
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M7Y-+LV\J<(K)%&0B%OE .#G/IQ5*UN]+DM?LJ22QQ.S@*Q(9B&VD#N<DU/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LW6$MY(;;[0[ +<H5 7.]N<#%:54=3L/[0AA3?L\J9902,@[>
MU &-<:7:FYM+:>_;=EC%&0/EPN3],=>:OVMC:070N1=K+\H&2PZJ,$_XU#>^
M'Q=3"1IV 5G?:B\DL ,9].*98^'_ )I)+T(QEE=S&.@!.1T[T $VDQ70NO/N
MXU#3,ZA<< X//Y4Z71+25U/VPJ06:(HP!PQR?J.U.'AX@AC<Y888_NQ@L#P3
M[;>,5!+X4CFAGB:]E5;AE9]HY4@DX4]ASTH &TJSU.2[A@NS\LBB0!00N,$
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M%% !1110 4444 (WW3]**&^Z?I10 +]T?2EI%^Z/I2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/T
MHH;[I^E%  OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2BAONGZ44 "_='TI:1?N
MCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (WW3]**&^Z?I10 +]T?2EI%^Z/I2T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=
M/THH;[I^E%  OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2BAONGZ44 "_='TI:1
M?NCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 (WW3]**&^Z?I10 +]T?2EI%^Z/I2T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C
M?=/THH;[I^E%  OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2BAONGZ44 "_='TI
M:1?NCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMZ@<U:NKIDO;U1/.84A\S]W+D[@0 !_=^E '145S]W-?V^CQ0A+E[K]WN<,
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MX;';VSU[T =516!_:6HW#LEM]F5X0S2F7.& 8@8].AR:CM_$4TT\$;0HGGW
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MG)]JHS^.;2'PX-7CLKJ63SS;M9@ 2JX/S@C_ &1S]* (QJ7CD8 \-::!P/\
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MCVJKI>M,?%,=E:PV<=G).Z)Y4*J2GE*XY'N37:O#%*4,D:.4.Y"R@[3ZCT-
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MWXR%/UYK-G\0W/E1O%]G7,L?F?,6"*6P5;T:K>EZA->B^-P(V-N04^7H>?\
M"J5MK,,-O!]NM")+YS@- $#,!G_@7 SF@#3T759M425W@$:J1L(;)/7@CL16
M;;ZS=VJN+C9(Y=Y/F8C<-VT)'[C%6!KEO;.@33W0SKYQ\L#E3T8X[T1:P+J_
ML[<:<H=L2;G928U920P]^* +J:DR:*VH702,*I<A<D =JRX/$US<&3R[6/$2
M;G)8\G<!@?G6Y$LJVD@O5A(&>%'R[??-8R^(;-6\J&Q.5#%@FT (!NS[\=J
M+]AJC7\-U*(@J0Y3<#U<9W#\#5 >(KA8I)3;(84?RA\QW9V!LGVYI-*U..6_
MM+:QA*6$\<LH=\;I"&&3Z]2>M69=;M(9&CDMBO48('+YP%^I'/TH IP^()8F
MN)9C'-#'*=TD;Y14RHR/7DU'>>(+L02QA8H)1C[\A#$DCA!WQGFK:ZJ@:"*/
M3E6&3.Y3M&Q,,<X[YV]*M65_!JEJ]VMCAHAN0R*.<C((- %:?Q-%'&VTQ>8
M.-V<,21M..AXJYH=Z]_9O<ON :3*JW\(V@X_6L./7H81=2ZCI\4=L3&QV(K8
M9E+<_P![ZUT.EWR7UH94MV@ ;:488].GJ* +]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<WX_C63P%K8=01]D<X/L*Z2N=\>?\B'K?\
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ML_VX]LLL'F6]\ZK$ R@Q>5N&_P!>>F*[L1HN,*HP,# Z4GE1[R_EKN/5L<T
M<?H_C.\U75[6T.F>3'-$KLS,0W*YW*.ZYXKLZ8(HPRL(T#*-H(49 ]*?0 55
MDL;6:X:>6WC>5H_*+,N<IZ?2K5% &=:Z)IEE(CVUE#$T9)4J.5)&#^E:-%%
M"5FR:#I4MJMM)I\#0*YD"%>-QZFM.B@"O;6=O9AUMX4B#MO8*,9;UJQ110!6
MO;&VU&V-M=PK-"2"4;ID=*K'0M+9D=K*)W3:%9@21M^[R?3-:5% &4GA[28U
MC\NQB7RG,B8R-I/7'/3VZ56L?"6D6-O/";99_M!<2O*,E@S;B/IGTK>HH 9'
M&D4:1H,(HVJ/04^BB@##FU#2TO;F%[9RRR#S9/+^4N5XY]<4R6\TFR8P"TE?
M"Y;9&6P,CJ?KBM)]+M9&E9H\^:XD?GJP&,_E44.BV<*R*!(WF<,7<DGD'^@H
M S)-8TVWN)II[22.&-"\DQC/[O)PP?TIB:EH<D.+6U9S,I4(%(7C!R>P[<UI
MW.@6%U)(TT;,)?\ 6)O.U^^".]*NA6*1",(VU49%^;[JGM0!1@DTZY>$-!M6
M1_(8.2"9%''U[]:1]2MM.BN'LXIY)" $5@=K@'!*_0GFM&#2+:&Y6X!>23.X
MLYSN8# /X"E&C6@>1BK'?_"6R%YR=OIDT 9FHWMO93K:'3&E4M$C$+D$,3P/
M<&I+.\T0WPL;>+;-(@!!4]/[I^F*TY]-M[F[CN9%8R1D%0&XR#D$CVID&D6E
MK=_:84*2$8.#P?<^_- %*VU[3$7RX8I4WNWE1^7@RD-M.T?6EDUK3WD;-M/*
MQ78VV'/7)VG\C5EM"L"(QY15HP1&P;E,MN)!]<U)'I5I$ %C/!SG/4X(R?S-
M &;#J&CVDH>*W92JEC*L9.Q./O$_45"_B/P\R.\F"97PX:/YB ,[C[8K6&C6
M*Q/'Y64D78P)ZCCC]*B7P_IZK$!$<PN6C)(RN>HZ=* *D.JV44-P\-N$^3SF
MP.'CSC.>YZT3R:%9-LDMOW<:AC)M++'GD#)Z$^U63X>LF!!$A7Y@%+<!6.2!
M[58N-'L[N4R31D[EVL@/RMCID>H[4 9!O-*_LNZOK>PGW0(',9!5]K],#/3V
MJ*'4-&TZWVW-J\!BDQ&Q4_O&7@8/KSTK<.D69@FA\L[)HUCD^;DJHP*CN-!T
M^YBCCFB+^625);D$]3]: &2ZS;O96]Q'A[:XW L0>  <\?48K-74_#T$'G?9
MFC4C:H=#EU.5.,]N"*W)--MI;:*"12R1C"\XZ_2J[Z!I\@3]T04 5&!Y49S_
M #H H_;-*TZ^BN([,K&]KYPG1#A$)&<^@Z&H3KNCSW,3Q0HZ/.7D=E.=X4[2
M/4G&*V+C1[2ZDC>96.R/RL!L!DZX([CBHE\/:>J*@A.U&+(,\)D$<?F: (/M
MFDNRJ]LZR*ZIM:,@H>>OL.?SK0TX6K62R6L;)#)DA6STZ=^U0G0[)EPZNQV,
MA8N<L&ZY]ZO0PK!$L:9VJ %![ #% %9=(T]4*"UCVEMQ!&<FK,$$=M$(HEVH
M.@R3C\ZEHH **** "BBB@ HHHH **** "BBB@ HHHH Q?$VG:KJFE?9]'U5M
M-NMX;SPN[Y1U&/>N0_X0OQ[_ -#[)_WX%>DT4 >;?\(7X]_Z'V3_ +\"C_A"
M_'O_ $/LG_?@5Z310!Y?>>%/'=G8SW+>.Y66&-I"HA'.!G'2N@^&>IWNL>!K
M.]U"Y>XN9&?=(^,G#'%=#K?_ " =0_Z]I/\ T$URGP@_Y)OI_P#O2?\ H1H
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MT3_KV7^M=/0 C?=/THH;[I^E%  OW1]*6D7[H^E+0!S_ (Y_Y$;6_P#KT?\
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M78F[=M&[&,XYQ2J=R@XQD=*6@!GE1XQY:XQC&.WI2E$(P5!'H13J* "BBB@
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MG_(AZW_UZ/\ RKHJYWQY_P B'K?_ %Z/_*@"+X=_\D^T3_KV7^M=/7,?#O\
MY)]HG_7LO]:Z>@!&^Z?I10WW3]** !?NCZ4M(OW1]*6@#G_'/_(C:W_UZ/\
MRJM\./\ DGFB?]>P_K5GQS_R(VM_]>C_ ,JK?#C_ ))YHG_7L/ZT =31110
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M7%M9R2PI<-<-!*6R,@$J"H]R*VM-N_MMDDQ^]DJW&.0<'^5 %RBLW6]2.E6
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MT]<Q\._^2?:)_P!>R_UKIZ $;[I^E%#?=/THH %^Z/I2TB_='TI: .?\<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(&4 GL ,5/HNC:GI6H7,L?DQV<S@+:"9G5!DEI!GHQS]T<4 =31110 4444
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MUO\ Z]'_ )56^''_ "3S1/\ KV']:L^.?^1&UO\ Z]'_ )56^''_ "3S1/\
MKV']: .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%)&BB,ZCG)3&/SW?I6]@9S@9J-8(UF>55 D? 9O4"@#F6\1WL4-H7A0RR/\
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M(U"J/H!0!+7.^//^1#UO_KT?^5=%7.^//^1#UO\ Z]'_ )4 1?#O_DGVB?\
M7LO]:Z>N8^'?_)/M$_Z]E_K73T (WW3]**&^Z?I10 +]T?2EI%^Z/I2T <_X
MY_Y$;6_^O1_Y56^''_)/-$_Z]A_6K/CG_D1M;_Z]'_E5;X<?\D\T3_KV']:
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M(/E^GI5"+Q!!*TB+!-YD(9IUXS$!GKZYP<8J)?%-E]K%JZR1S;-Q5\#:=NX
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MG_(AZW_UZ/\ RKHJYWQY_P B'K?_ %Z/_*@"+X=_\D^T3_KV7^M=/7,?#O\
MY)]HG_7LO]:Z>@!&^Z?I10WW3]** !?NCZ4M(OW1]*6@#G_'/_(C:W_UZ/\
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MIDMC,[HLF"'0X96!R"/H15^B@#G(/#,PO[6ZU#6;N_%JWF112JJJ'QC=\H[
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M]'_E5;X<?\D\T3_KV']: .III(4$DX Y.:=56^MFO+1X%F:+?C+ 9XSR/QH
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M*C F-MK>QKG?[ NEWH#'+;[P_E2N293C&6;'TP*F.CW\<!6*:-W975F=B.&
M&>.XQ0!MK<PN3MD5@,Y(/ QUYJ3>N<;ADC(&:YQ/#TD,!AB2$0AV;R=Q"R@G
M.&]*6Q\/S6US]HDF#S"5&5LGY4"X*#VH Z#SH]SCS%RGWAN^[]:<S 8R0,G
MYK N]":6^N9HHH2DTBR.C,0)<+C#8].HIVH:1?7-E:6R31'RE^9VR&#\88'V
MH W-Z#=EQQUYZ4%T')=1QGD]JY$Z+>M$C&WC+-<?O%+/^]7)Y?T'^-6$\-7"
MEY'>.9OD C=F VC.4SZ<C\J .GW#'WA@=\TA==NXL OKGBN7N/#=]-%Y:7@1
M JNJ@G[^>0?]G:,5;N=#GET:VLXY6_=ON='DX8<\9QT';B@#=W+@DL,#KSTH
MWKG&X9QG&:YB?PY>NTNRZS&X4>6[GD+UR<=6[_2K$>B7$0EVB,R%4V3.Y+C!
M!V'VXZT ;CW4,;E&D7> "5SR 3C./2I-P! + $G &:Y:;PU<W%U)<2&%9+A=
MLK*S95=^[ /T.*D70+UKJ":>X#E&Y"N1@ _*>G7'!H Z4LH(!8 GH,]:3S$X
M.]<'H<]:Q]0TJ>ZO9I49/GC"I(6(:/U 'HW?ZU5'APRK^]6-5 'EQ*[%8OFR
M0/J* .CWKP-PR>G/6D\Q.N]<9QU[^E<<_AR_DNY84D\O; %AN\MF([B?E]2!
MQ4\7A68PQK--N9!)UD)&\KA7'3!SR: .JWJ.K#CCK48NH6?:LBDY(.#G!'4'
MTKFY=!U-K2:V26WV2G<Q9F+[]N-V[''/.*;;^%[NWB,:S1!2SN^TG]\6QG=[
M<'F@#JMZG&&'/3GK3ZY<>&[CS_M DCCD79Y2JS$0@-D@>V.*Z8$D<C% #J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "LGQ'JDVCZ+->6\:R3AECC5SA=S,%&<=N:UJQ/
M%6GW.IZ#-;6:J]P'21$<X#%6#8SVSB@"C_:/B#3-3T^+5?[/EMKR;R ;8.&1
MB"0>>W%=37)S+K>M:II9N='^P6]I<_:'D>X23=A2 H"GJ<UUE !37;:C-SP"
M:=3)!NC<=,@B@#BUUWQ/-H#Z_$FEK9"-YU@;?YGEKG@GIG KLK6<75G#<!2H
MEC5P#VR,UQ$=KXCM_"DGAU=$60^4]NMT+I A!SA\=>AZ5VME ;:PM[=B"T42
MH2.^ !0!/1110!S=U?Z]=ZU>66D_8(XK0('>ZW$NS G@+V%7= U&ZU"RE-ZD
M27-O.\$GE$E&*GJ,\X-9\JZQIFOW]U9Z5]OM[L1D,LZ1E"H(((;KZU=\.6EW
M:V-P]]$L-Q<W,D[0JX;RPQX&1U.!0!M5SOCS_D0];_Z]'_E715SOCS_D0];_
M .O1_P"5 $7P[_Y)]HG_ %[+_6NGKF/AW_R3[1/^O9?ZUT] "-]T_2BAONGZ
M44 "_='TI:1?NCZ4M '/^.?^1&UO_KT?^55OAQ_R3S1/^O8?UJSXY_Y$;6_^
MO1_Y56^''_)/-$_Z]A_6@#J:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **3O1D>HYZ>] "T444 %%)D9/
M/3K[49'YT +1110 44A(!Y(&>E&??I0 M%%% !11320.I YH =1132P4$D@
M=SVH =7.^//^1#UO_KT?^5=%VKG?'G_(AZW_ ->C_P J (OAW_R3[1/^O9?Z
MUT]<Q\._^2?:)_U[+_6NGH 1ONGZ44-]T_2B@ 7[H^E+2+]T?2EH Y_QS_R(
MVM_]>C_RJM\./^2>:)_U[#^M6?'/_(C:W_UZ/_*JWPX_Y)YHG_7L/ZT =311
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M17+VOB.0VZQ2H6G/[PLK9'E[L9!^IQ5@>(V+O$8HUEBR9%9\  8X!QRQST%
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M;6;J]DMX(0D1>2-F=),X0D_+G'WN.14\^K7%G?7ADB\RV1U5-I^;.S. ,=*
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MQR2MA<#J#_M>U '245S\NONZ1?9A"')4R>8W"*7VD''?BHI_%/V>/ MI))
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MGZ44-]T_2B@ 7[H^E+2+]T?2EH Y_P <_P#(C:W_ ->C_P JK?#C_DGFB?\
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M)KJ-K:&\BE=V<Y,+QL%9"![D\^U;FK:1;:U:I:WF\P+*LC(K8#[3D ^U8K^
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M)'6IJ %HIH8-]T@X.#@T.ZHC.[!549+$\ 4 .HJ*.>.95>-PRL-RD=Q4GXT
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MJ\=O;+91R/.%#N\?W688RI&.AR?2H+6+74ACE>XGDG\M6,<FW;O(.0<#H.*
M%_LK5PFZ&7RIUP&9I"RS')#-C/'!R!ZBI=.TW4;.ZOI'N9)2Z,(5D;Y6YRO?
M.1TJK&NOO9%FN;@2K&[JH4 F3C"G(Y&<]/SIMRNM-<^;&+GS0'#\#8BDK]SC
M)./K0 D6C:MY4S33%90";<><0%;CJ,GT/K5O5].U>\OD-NXCB5-I97*D@J<]
M_4CM^-5YH=5GN=.6<W$GESQL=J@(5"G+-D9W9[?I4NH/K;ZA.+43Q0DA >"
M-R_,N1W!;N>E $$^AZM'#,MI=F+>S@%IB?DRI4#)XZ,/QJ>/1-06 L)Y?/
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MC&2#^/0\U4.CZFFJQLM\Z6*2?NT63)49!YR><\^N*=]FUFZL)HYKJZ3,3D;
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M715SOCS_ )$/6_\ KT?^5 $7P[_Y)]HG_7LO]:Z>N8^'?_)/M$_Z]E_K73T
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M\Z2'Q#J<L)D-NB28*K R'<WRY$O^[GM0!UE%8C7NHQ:7>.[6YN8" KE2J,"
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M".=-DBY7(./7%*T,;NCL@+)G:?3-244 )@>@J*&WBMT*11JBEBV .,GK4U%
M#&170J1\K#!QZ41Q)%$L:* BC %/HH 3 ]!1@>E+10 F!C&!1@>@I:* $P/0
M4N!Z444 )@#H!1@>@I:* $P/2C ]!Q2T4 &!CI5>&S@@E>2-,/)]XDDG]>E6
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\>
M?\B'K?\ UZ/_ "KHJYWQY_R(>M_]>C_RH B^'?\ R3[1/^O9?ZUT]<Q\._\
MDGVB?]>R_P!:Z>@!&^Z?I10WW3]** !?NCZ4M(OW1]*6@#G_ !S_ ,B-K?\
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M4\/W=S?:-#/=M&UP2P?R^F0Q&* -2BBB@ HHHH **** "BBB@ HHHH ****
M"N=\>?\ (AZW_P!>C_RKHJYWQY_R(>M_]>C_ ,J (OAW_P D^T3_ *]E_K73
MUS'P[_Y)]HG_ %[+_6NGH 1ONGZ44-]T_2B@ 7[H^E+2+]T?2EH Y_QS_P B
M-K?_ %Z/_*JWPX_Y)YHG_7L/ZU9\<_\ (C:W_P!>C_RJM\./^2>:)_U[#^M
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MWO(8S#(#L81]26) )]\?G6U<:187>//MD?'3(]L?ECBF3:-:2&$"-4CC<.5
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MBJ%=JF5AU/M]35N+2+"W""*W1=A#+WY'?ZTV71M/F,Q>V4F<@R8)&2._'0T
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M:IOD0(YR<,.W%.71M/2:&86RF2$ 1L221C^OO0!G:AK:6UG>2VEKN>(.L4A
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M*JJ6E&[ ]3WH L?\(+9_]!?7?_!C)_C1_P (+9_]!?7?_!C)_C5C_A._"O\
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M '^%'_"=^%?^@_8?]_A0!T-%<]_PG?A7_H/V'_?X4?\ "=^%?^@_8?\ ?X4
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MU((-6;?PQI%U*L,6MZX9"H;:=0D!Y ..O7GI4!U/P3Y[2_\ "1VVUE(V>>N
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MO"'_ $ +/_OFC_A77A#_ * %G_WS73T4 <Q_PKKPA_T +/\ [XH_X5UX0_Z
M%G_WS73T4 <Q_P *Z\(?] "S_P"^:/\ A77A#_H 6?\ WS73T4 <Q_PKOPA_
MT +/_OFC_A77A#_H 6?_ 'S73T4 <Q_PKKPA_P! "S_[YH_X5UX0_P"@!9_]
M\UT]% ',?\*Z\(?] "S_ .^:/^%=^$/^@!9_]\UT]% ',?\ "NO"'_0 L_\
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MA_T +/\ [YH_X5UX0_Z %G_WS73T4 <Q_P *Z\(?] "S_P"^:/\ A77A#_H
M6?\ WS73T4 <Q_PKKPA_T +/_OFC_A77A#_H 6?_ 'S73T4 <Q_PKKPA_P!
M"S_[YH_X5UX0_P"@!9_]\UT]% ',?\*Z\(?] "S_ .^:/^%=>$/^@!9_]\UT
M]% ',?\ "NO"'_0 L_\ OFC_ (5UX0_Z %G_ -\UT]% ',?\*Z\(?] "S_[X
MH_X5UX0_Z %G_P!\UT]% ',?\*Z\(?\ 0 L_^^:/^%=>$/\ H 6?_?-=/10!
MS'_"NO"'_0 L_P#OFC_A77A#_H 6?_?-=/10!S'_  KKPA_T +/_ +YH_P"%
M=>$/^@!9_P#?-=/10!S'_"NO"'_0 L_^^:/^%=>$/^@!9_\ ?-=/10!S'_"N
MO"'_ $ +/_OFC_A77A#_ * %G_WS73T4 <Q_PKKPA_T +/\ [YH_X5UX0_Z
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DE]1^=&Y?4?G110 ;E]1^=&Y?4?G110 C,NT\CIZT444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mbrx20220406_def14aimg002.jpg
<TEXT>
begin 644 mbrx20220406_def14aimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /I P8# 2(  A$! Q$!_\0
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M6B@!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_ '1^5&U?[H_*EHH
M3:O]T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH CE5=O
MW1U]**67[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW?QHHE^[^-% #E^Z/
MI2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M(OW1]*6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW?QHHE^[^-% #
ME^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M(OW1]*6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW?QHHE^[^
M-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M(OW1]*6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW?QHH
ME^[^-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M(OW1
M]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW
M?QHHE^[^-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M
M(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9'+%*I:.174$
MJ2K9 (ZBG9'K0 M%&1ZTF1ZT +129 QDCGI1F@!:*3(]:-Z[2VX8'4YH 6BJ
MPO[-H5F%W;F)VVJXD&UCZ YZU9S0 455O-0L]/@,]Y<Q01!@I>1@H!/ 'XU9
MS0 M%)D>M5TU"RDN3:I>6[7 ZQ"4%Q^&<T 6:*3(]:,CUH 6BDR/6D=U1&=F
M 51DD]A0 ZBJ-OJ^G7<T4-O>V\LLT7G1HC@EDZ;AZBKN1ZT +129'K4-S=6]
MG;27%S,D4,8W/([8"CU- $]%,1TD171@RL 5(/44[(H 6BHS-$)1"94$A&X)
MN&XCUQZ4_(]: %HIKR)'&SNP5%!+$G@ =ZI6VKZ=>R11VM]!,\L7G1A'!W)G
M&X>HS0!?HJM=WUK80B:[N(X(RP0/(V 6/ 'UIUS=V]FJ-<SQQ*[B-"[8!8]!
M]30!/16>-:TQI4C%_;^8\QMU7S!DR#DH/?VJ^'5ONL#VX- "T4F1ZT9&.HH
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M?MW8ZYV_-NZ5Z&]M81K#%)!;JBMB%&1<!O\ 9'K]*=%%9S3?:T@C:8Y7S?+
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M10 4444 %%%% !1110 4444 ,E^[^-%$OW?QHH <OW1]*6D7[H^E+0 4444
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M1Q::I(D#?-M5-@V]>2N>YI&;6YM$FN7N7ANUM9C<0(',C,<A<=ACMCM7?T4
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MHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW?QHHE^[
M^-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M(OW1]*6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DOW?QH
MHE^[^-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4M(OW
M1]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DO
MW?QHHE^[^-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?NCZ4
MM(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!DOW?QHHE^[^-% #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+]W\:*)?N_C10 Y?
MNCZ4M(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &2_=_&BB7[OXT4 .7[H^E+2+]T?2EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFP\HO5;8/7&WFN@HH R=6O-7M98AINDI?(P.\M<B+8?Q!S6>=7\5 <>%X?\
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MZ6B@#,U2[U2UBA;3M,2]=C^\5IQ%LX]2#FLW^U_%/_0KP_\ @P7_ .)KI:*
M,]KC4/['^T+8*;_8#]E,PQN_N[\8_&LK^U_%/_0KP_\ @P7_ .)KI:* ,O2;
MS5;OS?[2TM;':1LVW EW_D!BL]M6\3J[!?#,3*&(#?;U&1V.-M=)10!B:;J&
MN7-YY=_HD=G!M)\U;L2<]A@ 4R]U+Q!!>21VF@1W-N"-DQO%0M^&WBMZB@#G
M(M6\3-,BR>&HD0L S_;U.T9Y.-O-:&JW>J6JQ'3=,6^+$APTXBV#ZD'-:=%
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M?^29Z)_UQ/\ Z$: .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW?4UUC31QG#R(IQG#,!Q0!S7Q!T&]\2^#[G2]/$9N9'C9?,;:/E8$\_A6*?
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M74_\(OHO]KQZK]@C^W1P?9TGR<B/&-OY<>M6-(T;3M!T\6.F6RVUL'9Q&I)
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M/^N)_P#0C3_B=_R3;7?^O8_S%,^%O_),]$_ZXG_T(T =A1110 4444 %%%%
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M%% !1110 4444 %%&11F@ HI,CUI: "BBB@ HHHH **** "BBC(H **,BB@
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MT% &7=^(I%6_1+93MD6&U8/CS2WRD^V#6;H_B,VFCV5I_KKI+/[0YD8DN-Q
M /J?>N@C\/:=%'8HL3$62LL)9R2,]<^OXTMOH>GVXACM@T36Z",&.3#;,YVM
M[9H Q;S6;K4]"BU"" P6[7$8*LQ650&&<CIZC%/G\6SV]C8:F]G&+&[D8'YS
MYB* QSC&"3CI[UM3:%83MEXWV^8)?+#D+O!SNQZUE2^'6O-0L_,@6"SM)6DV
M"3>LF01@+V!SSG\* &?\)9*T+/':!E%NMP9EW%(U) (;C.1G.!VK2U#6_LGA
MF36(/)N0L0==C_(^2!P?3FK46F1PVK6\<UPB' 7$AS&!T"^@IK:+8-H[:3Y
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M'.?Q-::6-M&C1I$JJ[F1@O&6/4_6JYTZW:[MWBD:(6S,_DQMA69AC+>O7O0
MFMS:?:Z:]SJ*"2&+Y@F,EVZ  =R?2N=L+*47NE:?J2M% UM/<"#S20CEAA,]
M]JL?ICVKJ72SU$ L(IQ#)P<YV./ZBHYH;!I8;:81-)R8T8Y8<<X[],T <D\A
MO_"UC;-$UQJ5V\EO;.7.419"!*6]E .>_'K6KK"P&[L=.CC^TZI.4+3YP8HT
MZRGT]AW)K7EM=.@>$R1PQMM\F+G;QUVC\J=#:V,S_;8$C=I0/WRG[P'3GVH
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MIF4Y?&1N/J:L111P1+%&JHBC"JHP!0!QT6JE[V'6Y' LX(TMFR> 67+D^X8
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M\'-=A-;17"J)8E?:=RY'(/J*C2TL[5EF6&&,QQ^6K@ ;5ZXSZ4 9^M?:5O\
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M. ,\]:K2>([Z+5;&U,ENT=X0A;;_ *DJQ!8^H?&%]ZZ,:=:""&(6\0CA&(E
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MR[)2J $.!_/'>GVQL[GS'@5#MD:-RJ8^8'!!H P(O$$ZZ!)(@G:Z@NA;7!N
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MH P3J.J07-K:S.8X;N7RUN7V,4PI..#CG'!-9M[=76EZIXAOK:Y!:WCM2P9
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MI6I365R;K= 8Q++' 6C3S/NDL.,&K;^,=)37)])#RO-;1^9<S)&3# ,9P[]
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M$3(R<5BW_P 2=.7P[J=_807+W=G$)!:S0,C[6^Y(1_</K0!AZIX!UB\TKQ#
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M3/L6+63<78,,,>.F!^%2Z]X1U'4_%6L:A'#;O!<Z(UE"9&&?-.>V.![T:O\
M$:V&IV=AH^Z=FU)+.>9XCY)Z[PC]"PK=?QCID6M3:3)%>+=1H[QAK<A9]@RP
MC/\ $1Z4 </J7P\U:4V\IMQ?";2X;"XMOMIA$10<G.#N4^@P>*NM\.[N;2O$
M=JZ0K+=W$4EG(9-S%$5?E9L9 )4_SI^F?$IM9LM.N%@;3VGU/[&4G@9Q(O.
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MGU"WOM)U.WM9O[/.GW GAWAD.#E?0@BLB[^'.K3Z9::?'KD8MTTU;":-XV*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>5?&O[OA;_L*+_2O5:\J^-?W?"W_847^E 'J@Z"EI!T%+0 R7[OXT42_=_&
MB@!R_='TI:1?NCZ4M ')?$[_ ))MKO\ U['^8IGPM_Y)GHG_ %Q/_H1I_P 3
MO^2;:[_U['^8IGPM_P"29Z)_UQ/_ *$: .PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
ME7QK^[X6_P"PHO\ 2O5:\J^-?W?"W_847^E 'J@Z"EI!T%+0 R7[OXT42_=_
M&B@!R_='TI:1?NCZ4M ')?$[_DFVN_\ 7L?YBF?"W_DF>B?]<3_Z$:?\3O\
MDFVN_P#7L?YBF?"W_DF>B?\ 7$_^A&@#L**** "BBB@ HHHH **** "BBB@
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MT@Z"EH 9+]W\:*)?N_C10 Y?NCZ4M(OW1]*6@#DOB=_R3;7?^O8_S%,^%O\
MR3/1/^N)_P#0C3_B=_R3;7?^O8_S%,^%O_),]$_ZXG_T(T =A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5?&O[OA;_L*+_2O
M5:\J^-?W?"W_ &%%_I0!ZH.@I:0=!2T ,E^[^-%$OW?QHH <OW1]*6D7[H^E
M+0!R7Q._Y)MKO_7L?YBF?"W_ ))GHG_7$_\ H1I_Q._Y)MKO_7L?YBF?"W_D
MF>B?]<3_ .A&@#L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KRKXU_=\+?]A1?Z5ZK7E7QK^[X6_["B_TH ]4'04M(.@I: &2_
M=_&BB7[OXT4 .7[H^E+2+]T?2EH Y+XG?\DVUW_KV/\ ,4SX6_\ ),]$_P"N
M)_\ 0C3_ (G?\DVUW_KV/\Q3/A;_ ,DST3_KB?\ T(T =A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>5?&O[OA;_L*+_2O5:\
MJ^-?W?"W_847^E 'J@Z"EI!T%+0 R7[OXT42_=_&B@!R_='TI:1?NCZ4M ')
M?$[_ ))MKO\ U['^8IGPM_Y)GHG_ %Q/_H1I_P 3O^2;:[_U['^8IGPM_P"2
M9Z)_UQ/_ *$: .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O*OC7]WPM_V%%_I7JM>5?&O[OA;_L*+_2@#U0=!2T@Z"EH 9+]
MW\:*)?N_C10 Y?NCZ4M(OW1]*6@#DOB=_P DVUW_ *]C_,4SX6_\DST3_KB?
M_0C3_B=_R3;7?^O8_P Q3/A;_P DST3_ *XG_P!"- '84444 %%%% !1110
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M2;VZ6YN+")YUMVMM_<Q,,%3ZC%6?[8TS_H(VG_?Y?\:/[8TS_H(VG_?Y?\:
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M_E_QH_MC3/\ H(VG_?Y?\: +M%4O[8TS_H(VG_?Y?\:/[8TS_H(VG_?Y?\:
M+M%4O[8TS_H(VG_?Y?\ &C^V-,_Z"-I_W^7_ !H NT52_MC3/^@C:?\ ?Y?\
M:/[8TS_H(VG_ '^7_&@"[15+^V-,_P"@C:?]_E_QH_MC3/\ H(VG_?Y?\: +
MM%4O[8TS_H(VG_?Y?\:/[8TS_H(VG_?Y?\: +M%4O[8TS_H(VG_?Y?\ &C^V
M-,_Z"-I_W^7_ !H NT52_MC3/^@C:?\ ?Y?\:/[8TS_H(VG_ '^7_&@"[15+
M^V-,_P"@C:?]_E_QH_MC3/\ H(VG_?Y?\: +M%4O[8TS_H(VG_?Y?\:/[8TS
M_H(VG_?Y?\: +M>4_&K[OA;_ +"B_P!*])_MC3/^@C:?]_U_QKRKXM:G::OJ
MOA?2]-GCO+P:@)6BMW#E0,=<=._Y4 >PCH*6D7[HI: &2_=_&BB7[OXT4 .7
M[H^E+2+]T?2EH 0C-<%KGP?\*Z[?37KPSVMQ,<NUM)M!;N=O(YKOJ* /*?\
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M/^?[4_\ OZO_ ,31_P *"\,?\_VI_P#?U?\ XFO5J* /*?\ A07AC_G^U/\
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MH+PQ_P _VI_]_5_^)KU:B@#RG_A07AC_ )_M3_[^K_\ $T?\*"\,?\_VI_\
M?U?_ (FO5J* /*?^%!>&/^?[4_\ OZO_ ,31_P *"\,?\_VI_P#?U?\ XFO5
MJ* /*?\ A07AC_G^U/\ [^K_ /$T?\*"\,?\_P!J?_?U?_B:]6HH \I_X4%X
M8_Y_M3_[^K_\31_PH+PQ_P _VI_]_5_^)KU:B@#RG_A07AC_ )_M3_[^K_\
M$T?\*"\,?\_VI_\ ?U?_ (FO5J* /*?^%!>&/^?[4_\ OZO_ ,31_P *"\,?
M\_VI_P#?U?\ XFO5J* /*?\ A07AC_G^U/\ [^K_ /$T?\*"\,?\_P!J?_?U
M?_B:]6HH \I_X4%X8_Y_M3_[^K_\31_PH+PQ_P _VI_]_5_^)KU:B@#RG_A0
M7AC_ )_M3_[^K_\ $T?\*"\,?\_VI_\ ?U?_ (FO5J* /*?^%!>&/^?[4_\
MOZO_ ,31_P *"\,?\_VI_P#?U?\ XFO5J* /*?\ A07AC_G^U/\ [^K_ /$T
M?\*"\,?\_P!J?_?U?_B:]6HH \I_X4%X8_Y_M3_[^K_\31_PH+PQ_P _VI_]
M_5_^)KU:B@#RG_A07AC_ )_M3_[^K_\ $T?\*"\,?\_VI_\ ?U?_ (FO5J*
M/*?^%!>&/^?[4_\ OZO_ ,31_P *"\,?\_VI_P#?U?\ XFO5J* /*?\ A07A
MC_G^U3_OZO\ \374^%_AQX=\)7376G6SM=,,>=.^]E&,';Z9[XKK:* $I:**
M &2_=_&BB7[OXT4 .7[H^E+55?NCZ4M %FBJU% %FBJU% %FBJU% %FBJU%
M%FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJ
MU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %
MFBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU
M% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %F
MBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
/ $TOW?QHJM)]W\:* /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
